1 The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I 2 interferons Luz E. Cabrera<sup>1,\*</sup>, Suvi T. Jokiranta<sup>2,3</sup>, Sanna Mäki<sup>1</sup>, Simo Miettinen<sup>1,4</sup>, Ravi Kant<sup>1,4,5</sup>, 3 Lauri Kareinen<sup>1,4</sup>, Tarja Sironen<sup>1,4</sup>, Jukka-Pekka Pietilä<sup>6,7</sup>, Anu Kantele<sup>6,7</sup>, Eliisa 4 Kekäläinen<sup>2,3,10</sup>, Hanna Lindgren<sup>11</sup>, Pirkko Mattila<sup>11</sup>, Anja Kipar<sup>4,8,9</sup>, Olli Vapalahti<sup>1,4,10</sup> 5 6 and Tomas Strandin<sup>1</sup> 7 8 <sup>1</sup>Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki, 9 Finland. 10 <sup>2</sup>Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland. 11 <sup>3</sup>Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, 12 Finland. 13 <sup>4</sup>Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland. 14 <sup>5</sup>Department of Tropical Parasitology, Institute of Maritime and Tropical Medicine, Medical University 15 of Gdansk, 81-519 Gdynia, Poland. 16 <sup>6</sup>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, 17 Finland. 18 <sup>7</sup>Meilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Inflammation Center, 19 Helsinki University Hospital and University of Helsinki, Helsinki, Finland. <sup>8</sup>Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty, 20 21 University of Zurich, 8057 Zurich, Switzerland. 22 <sup>9</sup>Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological 23 Sciences, University of Liverpool, Liverpool L3 3RF, UK. 24 <sup>10</sup>Division of Virology and Immunology, HUSLAB Clinical Microbiology, HUS Diagnostic Center, 25 Helsinki University Hospital, Helsinki, Finland. 26 <sup>11</sup>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. 27 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 28 Abstract

29 The severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a critical arm of the innate immune response and are major mediators of inflammation, but their role in 30 COVID-19 pathophysiology remains poorly understood. We conducted transcriptomic 31 32 profiling of neutrophils obtained from patients with mild and severe COVID-19, as well as 33 from SARS-CoV-2 infected mice, in comparison to non-infected healthy controls. In addition, 34 we investigated the inflammasome formation potential in neutrophils from patients and mice upon SARS-CoV-2 infection. Transcriptomic analysis of polymorphonuclear cells (PMNs). 35 36 consisting mainly of mature neutrophils, revealed a striking type I interferon (IFN-I) gene signature in severe COVID-19 patients, contrasting with mild COVID-19 and healthy controls. 37 Notably, low-density granulocytes (LDGs) from severe COVID-19 patients exhibited an 38 39 immature neutrophil phenotype and lacked this IFN-I signature. Moreover, PMNs from severe 40 COVID-19 patients showed heightened nigericin-induced caspase1 activation, but reduced responsiveness to exogenous inflammasome priming. Furthermore, IFN-I emerged as a 41 42 priming stimulus for neutrophil inflammasomes, which was confirmed in a COVID-19 mouse 43 model. These findings underscore the crucial role of neutrophil inflammasomes in driving 44 inflammation during severe COVID-19. Altogether, these findings open promising avenues for targeted therapeutic interventions to mitigate the pathological processes associated with the 45 46 disease.

47

48 Keywords: inflammasome, neutrophils, COVID-19, type I interferon, inflammation, innate immunity. 49

### 50 Introduction

51

Severe COVID-19 is characterized by a dysregulated immune response with an excessive 52 53 production of pro-inflammatory cytokines and chemokines. Type I interferons (IFN-I) are 54 critical antiviral cytokines in the innate immune responses against viral infections, drawing 55 particular attention amidst the COVID-19 pandemic <sup>1–3</sup>. While the IFN-I response helps to limit 56 virus replication<sup>3</sup>, its prolonged and uncontrolled activation is detrimental to the overall health 57 of the patient <sup>4</sup>. As part of the pro-inflammatory response, neutrophils are rapidly recruited to 58 the site of infection in response to SARS-CoV-2 infection <sup>5,6</sup>. Prominent neutrophil recruitment in severe COVID-19 is associated with an increased number of immature low-density 59 granulocytes (LDGs) in the circulation <sup>7–9</sup>. The increased production and subsequent early 60 61 release of immature cells from the bone marrow occurs in response to emergency myelopoiesis 62 <sup>9</sup>. This process is initiated by the body to enable the recruitment of innate immune cells into 63 the tissues and to replenish the depleted leukocyte pool, in an effort to combat viral infections including SARS-CoV-2<sup>10</sup>. However, the premature release of these cells could be associated 64 65 with the increased degranulation and formation of neutrophil extracellular traps (NETs) reported during SARS-CoV-2 infection, to which LDGs have a higher propensity than 66 polymorphonuclear cells (PMN) <sup>5,6,11</sup>. 67

68

69 Neutrophils are involved in several aspects of inflammatory processes, including the release of 70 reactive oxygen species (ROS) and other pro-inflammatory mediators such as Interleukin-6 71 (IL-6) and IL-8. In addition, recent reports on COVID-19 highlight that neutrophils could be a 72 major source of inflammasome derived IL-1 $\beta$ , which has been implicated as a substantial contributor to COVID-19 pneumonia <sup>12</sup>. Inflammasomes are intracellular multiprotein 73 74 complexes involved in the inflammatory response. In the presence of a pathogen, antigen medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

75 recognition by the immune system triggers the assembly of the inflammasome, a step known 76 as the first signal. This is followed by the recruitment of adaptor molecules that activate NODlike receptor (NLR) family members and the binding of the apoptosis-associated speck-like 77 78 protein (ASC), finally activating the inflammasome complex <sup>13</sup>. The triggered assembly of this 79 complex is known as the second signal. Studies have shown that SARS-CoV-2 infection 80 induces significant inflammasome activation in circulating and lung-infiltrating myeloid cells, such as monocytes and neutrophils <sup>14–17</sup>. However, while the precise mechanism by which 81 82 inflammasomes are activated in monocytes/macrophages is well established, less is known 83 about molecular mechanisms of inflammasome formation in neutrophils. Thus, this study 84 investigates the inflammasome formation in neutrophils during COVID-19 in more detail, also focusing on the different developmental stages of these cells. In addition, a recently established 85 86 COVID-19 mouse model served to further explore the role of IFN-I in neutrophil 87 inflammasome assembly.

### 88 Materials and methods

### 89 **Patient population**

90 Adult clinical patients with confirmed COVID-19 (RT-PCR positive for SARS-CoV-2) at 91 Helsinki University Hospital (HUH) (hospitalized: n = 34; outpatients: n = 8) were enrolled in 92 the present study. Blood samples were collected during hospitalization for the severe COVID-93 19 group, and after confirmation of diagnosis for the mild COVID-19 outpatient group. 94 Samples for RNA sequencing were collected in 2020 and representing infections by the original 95 and early SARS-CoV-2 variants, whereas samples for ex vivo culture experiments were 96 collected in 2021-2022 likely representing infections by omicron subvariants of SARS-CoV-97 2. As controls, healthy blood donors were included for RNA sequencing (n = 7, age 57  $\pm$  7, 98 male/female 3/4) and *ex vivo* culturing experiments (n = 9, age  $38 \pm 14$ , male/female 4/5). The 99 study was approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa 100 (HUS/853/2020, HUS/1238/2020). All volunteers gave a written informed consent, in 101 accordance with the Declaration of Helsinki. For clinical correlation analysis, severe COVID-102 19 patients were further categorized by severity based on their need for hospitalization and 103 oxygen supplementation, as described previously <sup>7</sup>. For each patient, medical history and 104 clinical data were collected through retrospective patient record review and are presented for the severe COVID-19, hospitalized patients in Table 1 and as previously described <sup>7</sup>. 105 106 Calprotectin was measured from serum (diluted 1:1000) by ELISA, according to the 107 manufacturer's protocol (calprotectin/S100A8 DuoSet kit, R&D systems).

### 108 Isolation of granulocytes from human blood

Blood samples from COVID-19 patients and healthy controls (HC) were collected in EDTA
vacutainer tubes and transported to the laboratory. Peripheral blood mononuclear cells

111 (PBMCs) or polymorphonuclear cells (PMNs) were isolated from whole blood by density gradient centrifugation using either Ficoll-Paque Plus (GE Healthcare) or Polymorphprep 112 113 (Axis-Shield) respectively, following standard procedures including the use of 2 mM EDTA in 114 PBS and red blood cell lysis with ACK lysis buffer (Lonza by Thermo Fisher). Subsequently, 115 isolation of CD66<sup>+</sup> granulocytes (low-density granulocytes, LDGs) from the PBMC fraction was performed using the CD66abce MicroBead Kit (Miltenyi Biotec, Germany) with an MS 116 117 column, according to the manufacturer's instructions. Both the positively selected CD66<sup>+</sup> LDGs and the isolated PMNs were then washed and counted, using a TC20<sup>TM</sup> Automated Cell 118 119 Counter (Bio-Rad Laboratories, Inc.) with trypan blue staining for dead cell exclusion. All 120 described procedures in this section were done at room temperature. An aliquot of cells was lysed in Trizol reagent (Thermo Fisher Scientific, USA) and stored at -80°C for later extraction 121 122 of total RNA and subsequent RNA sequencing (RNA-seq) analysis.

### 123 Caspase1 activity

124 Caspase1 activity was assessed in isolated cells after 2 h of culture (1 million cells/ml) using 125 the caspase-Glo<sup>®</sup>1 inflammasome assay (Promega) according to the manufacturer's protocol, 126 with 2.5  $\mu$ M nigericin (Invivogen) treatment as the activator. The resulting luminescence was 127 measured by a Hidex Sense microplate reader (Hidex).

### 128 Soluble factor stimulation assays

Isolated granulocytes from HC and COVID-19 patients were cultured at 2 million cells/ml in RPMI 1640 supplemented with 10% fetal bovine serum (R10) at 37°C. Cells were primed (1<sup>st</sup> signal) with either LPS (20 ng/ml, Sigma Aldrich) or IFN-I (combination of  $2.7*10^4$  IU/ml IFN-α and IFN-β, Immunotools) for 4 h, followed by activation (2<sup>nd</sup> signal) by 2.5 µM nigericin or monosodium urate crystals (MSU, 100 µg/ml, Invivogen) for an additional 4 h. For the 24 h stimulation experiments, nigericin was added to the cultured cells, in the presence or absence

of inflammasome inhibitors MCC995 (2  $\mu$ g/ml) and Ac-YVAD-FMK (20  $\mu$ g/ml, both from Invivogen).Cells were pelleted by centrifugation at 400 G for 5 min and stored in Trizol at – 80°C for later RNA extraction whereas supernatants were used to measure IL-1 $\beta$ , IL-18, myeloperoxidase (MPO) and IL-8 by ELISAs according to the manufacturer's protocols (DuoSet kits from R&D systems). LDH was measured in supernatants using Cyquant LDH cytotoxicity assay (ThermoFisher). HL-60 cells (ATCC #CCL-240) were activated similarly to neutrophils after a 5-day differentiation period induced by 1 % DMSO.

142

### 143 Virus propagation

144 The SARS-CoV-2 hCoV-19/Finland/THL-202117309/2021 (delta strain B.1.617.2) and the 145 mouse-adapted strain MaVie<sup>18</sup> were propagated in VeroE6-TMPRSS2 cells (kidney epithelial cells expressing the transmembrane protease serine 2)<sup>19</sup> grown in DMEM supplemented with 146 147 10% inactivated FCS, 100 IU/mL Penicillin, 100 µg/mL Streptomycin and 2 mM L-glutamine 148 at 37°C. The virus was purified from supernatants by ultracentrifugation (SW28 rotor, 27,000 149 rpm, 90 min, +4 °C) through a 0.22 µm-filtered 30% ultra-pure sucrose cushion (in PBS), to 150 obtain virus preparations free of cell culture contaminants. Virus titers were calculated by the 151 median tissue culture infectious dose (TCID50) after assessing cytopathic effects by crystal violet staining of cell cultures infected for 5 days with serially diluted virus. 152

153

### 154 **RNA sequencing**

Neutrophils isolated from different cohorts comprised three PMN groups (severe COVID-19,
mild COVID-19, and healthy controls), and one LDG group (given that these cells were rare
in mild COVID-19 patients and HC, only LDGs from patients with severe COVID-19 were
included).

159 cDNA synthesis from total RNA was performed according to Takara SMARTseq v4 Ultra-low 160 input RNA kit for Sequencing user manual (Takara Bio, Mountain View, CA, USA) followed by Illumina Nextera XT Library preparation according to Illumina Nextera XT Reference 161 162 Guide (Illumina, San Diego, CA, USA). UDI index setup was used for the Nextera XT libraries. Library quality check was performed using LabChip GX Touch HT High Sensitivity assay 163 164 (PerkinElmer, USA) and libraries were pooled based on the concentrations acquired from the 165 assay. The pooled libraries were quantified for sequencing using KAPA Library Quantification Kit (KAPA Biosystems, Wilmington, MA, USA) and sequenced on the Illumina NovaSeq6000 166 167 system for 200 cycles using S1 flow cell (Illumina, San Diego, CA, USA). Read length for the 168 paired-end run was 2x101 bp.

169

### 170 **RNA data analysis**

171 Principal Component Analysis (PCA) was performed on the normalized gene expression matrix using the Chipster software <sup>20</sup> to identify patterns in the data and reduce the 172 173 dimensionality of the dataset. The top principal components were selected based on the 174 percentage of variance explained. For enrichment analyses, Gene Set Enrichment Analysis 175 (GSEA) and Over-Representation Analysis (ORA) were performed on the top 5000 DE genes identified by DESeq2 (adjusted P value < 0.05, log2FC >1) using ExpressAnalyst <sup>21</sup>. GSEA 176 177 was used to identify enriched signaling pathways using the Reactome database, while ORA 178 was used to identify enriched pathways using the KEGG database. The resulting p-values were 179 corrected for multiple testing using the Benjamini-Hochberg method, and pathways with a 180 corrected p-value <0.05 were considered significant.

181 To visualize the expression patterns of the differentially expressed (DE) genes, the data was 182 analyzed using the AltAnalyze software <sup>22</sup>, which selected the top 95 genes based on correlation 183 and determined the heatmap clustering, using the Euclidean distance metric and the complete

linkage method. Then, the obtained heatmap was re-generated using heatmapper.ca<sup>23</sup> for better
visualization.

CIBERSORTx, a machine learning algorithm that infers cell type proportions using a reference 186 187 gene expression matrix of known cell types (25) was used to perform RNA-seq deconvolution on the gene expression data to estimate the abundance of immune cell types in the samples <sup>24</sup>. 188 189 The signature matrix used was taken from Lasalle *et al.*<sup>8</sup>. This reference matrix made use of a published whole-blood single-cell dataset <sup>9</sup>, and included the main immune cell types: 190 191 monocytes, NK cells, T lymphocytes, B lymphocytes, plasmablasts and neutrophils, the latter 192 subclassified into mature and immature. The smaller subsets of granulocytes (eosinophils and 193 basophils) are not considered separately and are most likely categorized as neutrophils in the 194 bulk data deconvolution. Nonetheless, the resulting cell type proportions were used to compare 195 the immune cell composition between groups.

Additionally, the determination of sample purity (>80% of "mature neutrophils" for PMNs or "immature neutrophils" for LDGs) served as a limiting parameter for the visualization of differentially expressed inflammasome related genes from the RNA sequencing results, which were selected and graphed in a heatmap using heatmapper.ca <sup>23</sup>, clustered by complete linkage and ordered by Spearman's rank.

201

### 202 Volcano Plots

To visualize differentially expressed (DE) genes between groups from human and mice RNAseq results previously identified by DESeq2, a volcano plot was generated using GraphPad Prism. Genes with a P-adjusted value (padj or FDR) <0.05 were considered significant. Similarly, RNA sequencing data from GSE93996 <sup>25</sup> was reanalyzed, and all DE genes in ATRA-differentiated HL-60 cells were visualized in a volcano plot.

208

### 209 Single cell transcriptomics data analysis

210 This study made use of the "COVID-19 Immune Atlas: integration of 5 public COVID-19 PBMC single-cell datasets" available online <sup>26</sup>. This standardized data collection contains cells 211 212 from different assays (10x 3' v2, 10x 3' v3, 10x technology and Seq-Well) and consists of a 213 total of 239,696 cells from the peripheral blood, 3,693 of which are neutrophils. These 214 neutrophils were further subclassified as mature (59%) and immature (41%), based on the 215 immune atlas predetermined cell classes. This was confirmed by a CD16b expression in mature 216 neutrophils, and a higher CD66b expression in the immature population. This data was obtained 217 from and analyzed in the Chan Zuckerberg CELLxGENE platform <sup>26</sup>.

218

# Reverse transcription and quantitative PCR (RT-qPCR) for human selected human genes

Total RNA was extracted from unstimulated or *ex vivo* stimulated PMNs using the Trizol reagent (Invitrogen, USA) according to the manufacturer's protocol. Subsequently, cDNA synthesis was performed using the RevertAid RT Reverse Transcription Kit (Thermo Scientific, USA) as per the manufacturer's instructions. Quantitative PCR (qPCR) was performed using the Stratagene model (Agilent Technologies) and SYBR Green/ROX master mix (Thermo Scientific, USA). The primer sequences for qPCR are presented in Supplementary Table S1.

Primer specificity was confirmed using melting curve analysis and dissociation curves. The relative expression levels of the genes of interest were calculated using the 2- $\Delta\Delta$ CT method and normalized to the expression of the housekeeping gene GAPDH. Baseline gene expressions of unstimulated samples were statistically assessed using the Mann-Whitney test, while the two-way ANOVA Tukey's multiple comparisons test was performed for the *ex vivo* stimulated samples.

### 234 Mouse infections

235 Experimental procedures were approved by the Animal Experimental Board of Finland (license number ESAVI/28687/2020). Female BALB/c mice (Envigo, Indianapolis, IN, USA; 7 to 8 236 237 weeks, n = 36 in total) were transferred to the University of Helsinki biosafety level-3 (BSL-238 3) facility and acclimatized to individually ventilated biocontainment cages (ISOcage; 239 Scanbur, Karl Sloanestran, Denmark) for 7 days with *ad libitum* water and food (rodent pellets). 240 For subsequent experimental infection, the mice were placed under isoflurane anesthesia and inoculated intranasally with 50 µL of SARS-CoV-2 MaVie strain (5\*10<sup>5</sup> TCID50/animal) or 241 242 PBS (mock-infected control). Daily weighting of all mice was performed, and their well-being 243 was carefully monitored for signs of illness (e.g., changes in posture or behavior, rough coat, 244 apathy, ataxia). Euthanasia was performed by cervical dislocation under terminal isoflurane 245 anesthesia. All animals were dissected immediately after euthanasia, and the lungs were 246 sampled for multiple downstream analyses. The infections were performed as 3 separate 247 experiments (exp) with 12 mice each: 1) Exp 1 included 8 mice infected with MaVie and 4 248 mock infected mice. At 2 days post infection (dpi), 4 infected and the mock infected mice were 249 euthanized; the remaining infected mice were euthanized at 4 dpi. The right lung was sampled 250 for virus-specific RT-qPCR (1/5) and neutrophil isolation (4/5), the left lung was fixed for histological and immunohistochemical examination. 2) Exp 2 included 8 infected and 4 mock 251 252 infected mice of which half were euthanized at 2 dpi and 4 dpi, respectively. From these mice, 253 both lung lobes were subjected to neutrophil isolation. 3) Exp 3 included 8 mice that were 254 infected and immediately inoculated intraperitoneally with 250 µg of anti-mouse IFNAR-1 (n 255 = 4) or IgG1 isotype control (n = 4) (Bio-X-Cell, New Hampshire, USA), and 4 mock-infected 256 animals. All mice were euthanized at 2 dpi. Each 1 1/5 of the left lobe was processed for virus-257 specific RT-qPCR and histology and immunohistochemistry respectively. The remaining 258 approx. 80% of the lungs served for neutrophil isolation.

### 259 Neutrophil isolation from mouse lungs

Neutrophil isolation was performed from the lungs of all mice. The dissected lung tissue was 260 chopped into small pieces using scissors and enzymatically digested with a cocktail of Liberase 261 262 (50 ug/ml; Roche #05401020001 from Merck) and DnaseI (100 ug/ml; Roche #11284932001 from Merck) in RPMI-1640 for 30 min at 37 °C. The resulting homogenate was diluted 10-263 264 fold in R10 and passed through a 70 µm Cell strainer (Pluriselect) to obtain a single-cell 265 suspension. Neutrophils were isolated by positive selection using Ly6G-binding magnetic beads and MS columns according to the manufacturer's recommendations (Miltenyi Biotec). 266 267 Neutrophils were isolated with a purity exceeding 95% based on flow cytometry analysis of 268 Ly6G expression.

269

### 270 **RNA** sequencing of mouse neutrophils

271 Mouse neutrophils were isolated, lysed in Trizol (Thermo Scientific) and the RNA extracted 272 in the liquid phase using chloroform. RNA isolation was carried out using the Rneasy micro 273 kit (Oiagen). Isolated RNA (1 ng) underwent whole transcriptome sequencing with 274 ribodepletion. Briefly, RNA sequencing was performed using the Illumina Stranded with 275 RiboZero library preparation method. Sample quality and integrity were assessed using TapeStation RNA analysis. Sequencing was conducted on the Illumina NextSeq platform, 276 277 followed by standard bioinformatics analysis for gene expression quantification.

278 The service was provided by the Biomedicum Functional Genomics Unit at the Helsinki 279 Institute of Life Science and Biocenter Finland at the University of Helsinki.

280

### 281 **RT-qPCR of mouse samples**

RNA was extracted from dissected lung samples (1/10 of the whole lung) of mice in Exp 1 and 282 283 Exp 3 as well as isolated neutrophils using Trizol (Thermo Scientific) following the

manufacturers' instructions. The isolated RNA was directly subjected to one-step RT-qPCR analysis based on a previously described protocol using primer-probe sets detecting the viral genome encoding for the RNA-dependent RNA polymerase (RdRp) <sup>27</sup>, subgenomic E <sup>28</sup> as well as mouse caspase1, IL1b and GAPDH (Applied biosystems #Mm00438023\_m1, #Mm00434228\_m1 and #Mm99999915\_g1 respectively, Thermo scientific). The PCRs were performed with TaqPath 1-step master mix (ThermoFisher Scientific) using AriaMx instrumentation (Agilent, Santa Clara, CA, USA).

291

### 292 Histology and immunohistochemistry

From animals in Exp 1 and Exp 3 the whole left lung (Exp 1) or 1/5 of the left lung (Exp 3) were trimmed for histological examination and routinely paraffin wax embedded. Consecutive sections (3  $\mu$ m) were prepared and routinely stained with hematoxylin-eosin (HE) or subjected to immunohistochemistry (IHC) for the detection of SARS-CoV-2 nucleoprotein (NP) <sup>29</sup> and Ly6G (neutrophil marker); for Exp 3, a further section of the infected lungs was stained for histone H3 (NET marker) <sup>30</sup>. All stains followed previously published protocols <sup>31</sup>.

299

### 300 Morphometric analyses

301 For quantification of SARS-CoV-2 antigen expression and the extent of neutrophil influx into 302 the lungs, a morphometric analysis was undertaken on the slides stained for SARS-CoV-2 NP 303 and Ly6G, respectively. The stained slides were scanned using NanoZoomer 2.0-HT (Hamamatsu, Hamamatsu City, Japan), and several sections of the lung of each animal were 304 305 quantitatively analysed using the Visiopharm 2022.01.3.12053 software (Visiopharm, 306 Hoersholm, Denmark). The morphometric analysis served to quantify the area, in all lung sections of an animal, that showed immunostaining for viral NP and Ly6G, respectively. In 307 308 Visiopharm, for each section, the lung was manually outlined and annotated as a Region Of

309 Interest (ROI), manually excluding artifactually altered areas. The manual tissue selection was 310 further refined with an Analysis Protocol Package (APP) based on a Decision Forest classifier, with the pixels from the ROI being ultimately classified as either "Tissue" or "Background". 311 312 This new "Tissue" ROI, regrouping the different lung samples analysed for each animal, was 313 further quantified by executing two APPs successively. The first APP was based on a Threshold 314 classifier and served to detect and outline areas with immunostaining. The second APP then 315 measured both the surface of the immunostained area  $(\mu m^2)$  and the surface of the "Tissue" 316 ROI ( $\mu$ m<sup>2</sup>). The percentage of immunostained area (%), expressed as the ratio between the 317 immunostained area and the total area, was obtained for each animal in Excel (Microsoft Office 318 2019; Microsoft, Redmond, Washington, United States), according to the following formula: 319 ([positive area  $(\mu m 2)$ ]/ [total area  $(\mu m 2)$ ]) x 100.

320

### 321 Statistical analyses

322 Statistical analysis was performed using GraphPad Prism 8.3 software (GraphPad Software, 323 San Diego, CA, USA) and R software v3.6.3 (R core team). Statistically significant correlations 324 between parameters were assessed by calculating Spearman's correlation coefficients, and 325 differences between groups were assessed with Mann-Whitney, Kruskall-Wallis or ordinary 326 one-way or 2-way ANOVA tests, depending on sample distribution and the number of groups 327 analyzed.

### 328 **Results**

# 329 Unsupervised RNA-seq analysis reveals a gene expression signature of circulating 330 neutrophils in COVID-19 that is strongly influenced by maturity

331

332 With our recent findings on increased frequencies of low-density granulocytes (LDGs, isolated 333 from the PBMC fraction) during COVID-19 and their likely relevant role in disease progression 334 <sup>7</sup>, we sought to understand in more detail how the transcriptomic profile of LDGs differs from their higher "normal" density counterpart, the circulating polymorphonuclear cells (PMNs)<sup>32</sup>, 335 336 typically consisting mainly of mature neutrophils. Neutrophils isolated from different cohorts 337 comprised three PMN groups (severe COVID-19, mild COVID-19, and healthy controls), and 338 one LDG group. We explored gene expression through RNA sequencing (RNA-seq) and 339 confirmed the distinctive gene signature of LDGs by principal component analysis (PCA) (Figure 1A), which revealed that the gene expression patterns of COVID-19 LDGs differed 340 341 from those of all PMNs regardless of the patients' disease state.

342 Functional enrichment analyses through gene overrepresentation and gene-set enrichment 343 analyses (ORA and GSEA, respectively) compared LDGs with PMNs from severe COVID-19 344 patients (Figure 1B). When considering the top 5000 differentially expressed genes (DEG), DNA replication and cell cycle were the most overrepresented pathways identified by ORA 345 346 (Figure 1B), which supported our previous findings suggesting LDGs to be predominantly 347 immature cells <sup>7</sup>. However, the next statistically significant result was an underrepresentation 348 of the NLR signaling pathway genes in LDGs in contrast with PMNs, highlighting that LDGs 349 have an inflammatory profile that differs from that of PMNs, also depicted in the GSEA (Figure 350 1B). Briefly, type I and II interferon signaling were among the most significantly enriched gene 351 sets in PMNs compared to LDGs. Further analysis showed that PMNs from severe COVID-19 352 patients had significantly enriched DEGs in inflammatory pathways such as NLR, tumor

necrosis factor (TNF), retinoic acid-inducible gene-I (RIG-I) like, autophagy, MAPK and
JAK/STAT signaling pathways compared to either HC PMNs or severe COVID-19 LDGs
(Supplementary Fig. 1A-D). Interestingly, many of the observed DEGs were linked to
inflammasome formation (Supplementary Fig. 1E-F). However, mild COVID-19 PMNs did
not significantly differ from HC PMNs in their inflammatory profile (Supplementary Fig. 1GH).

Additionally, we performed unsupervised Iterative Clustering and Guide Gene Selection (ICGS), which identified the top DEGs and classified the samples into two major clusters: a first one containing all isolated LDG samples, and a second one comprising all isolated PMN samples (Figure 1C). The former cluster consisted of many neutrophil marker genes (e.g. *CEACAM8, MMP8, DEFA*), while in the latter cluster the most significantly upregulated genes in the severe COVID-19 subgroup were mainly interferon inducible (e.g. *OAS1, OAS2, IF144L, IFITM3, IFIT2*) as well as some inflammasome related (*CASP5, CARD16*) genes.

- 366
- 367

# 368 Mature neutrophils from severe COVID-19 display a strong IFN-related gene expression 369 signature

To gain a comprehensive understanding of the cellular composition within PMN and LDG fractions, we performed a deconvolution of the RNA-seq data, which verified that most cells present in the samples were neutrophils. This analysis also demonstrated that cells in the LDG fraction were predominantly immature neutrophils, meanwhile PMNs were composed of mainly mature neutrophils (Figure 2A). Subsequently, gene expression analysis of PMNs and LDGs containing high purity of mature neutrophils and immature neutrophils (over 80%), respectively, confirmed that mature neutrophils from severe COVID-19 displayed an increased

expression of type I IFN related genes, while immature neutrophils from severe COVID-19distinctively lacked this signature (Figure 2B).

379

Inflammasomes are activated in severe COVID-19 PMNs, but not directly by SARS-CoV 2

382 Looking more closely into PMN fractions, ORA identified the inflammasome related NOD-383 like and RIG-like receptor signaling pathways among the most significantly overrepresented 384 pathways, differentially expressed in severe COVID-19 PMNs versus HC PMNs (Figure 3A) 385 or mild COVID-19 PMNs (Figure 3B). The increased expression of selected IFN-I (OAS1, 386 OAS2, and IFIT1) and inflammasome related genes (CASP1, CASP5, NLRC5 and NAIP) was 387 confirmed by RT-qPCR. However, some inflammasome related genes (IL-1B, NLRP3 and 388 *NLRC4*) were seemingly downregulated, although not statistically significant (Supplementary 389 Fig. 2).

390 Given the strong upregulation of many inflammasome related genes during severe COVID-19. 391 we assessed whether PMNs exhibit active inflammasome formation in vivo. To evaluate 392 spontaneous inflammasome mediated cytokine secretion, fresh PMNs isolated from severe 393 COVID-19 patients and HC were cultured ex vivo overnight. We measured the levels of IL-1β 394 and IL-18 in the supernatant and found that IL-1ß secretion was significantly increased in the 395 supernatant of severe COVID-19 PMNs compared to HC PMNs (Figure 3C), whereas the IL-396 18 levels did not differ significantly (Figure 3D). Additionally, since SARS-CoV-2 viral particles were previously implicated to induce inflammasome formation in macrophages <sup>17</sup>, the 397 398 IL-1β and IL-18 levels after HC PMNs exposure to SARS-CoV-2 were also assessed but no 399 significant effects in the secretion of these cytokines were observed (Figure 3E, F).

400 The spontaneous secretion of IL-1 $\beta$  by COVID-19 PMNs suggests that these cells are actively 401 producing and releasing IL-1 $\beta$  through inflammasome formation which is dependent on caspase1 activity <sup>33</sup>. We assessed caspase1 activity in response to the second signal required 402 403 for inflammasome activation, induced by nigericin, and observed increased caspase1 activity 404 in severe COVID-19 PMNs compared to HC PMNs (Figure 3G). These findings suggest that 405 severe COVID-19 PMNs have an increased capacity for inflammasome activation, potentially 406 due to an existing priming signal during acute disease in vivo. However, no significant 407 difference in caspase1 activity between non-exposed and virus-exposed PMNs were observed 408 (Figure 3G), indicating that caspase1 activation in COVID-19 PMNs is not directly triggered 409 by the virus.

410

## 411 Activation of neutrophil inflammasome related pathways during respiratory distress is 412 not specific to COVID-19

We also reanalyzed the RNA-seq data previously generated by LaSalle et al.<sup>8</sup>, focusing on 413 414 neutrophil transcriptomics in patients with COVID-19 as compared to non-COVID-19 patients exhibiting similar respiratory symptoms, as well as to healthy controls. Our analysis included 415 416 IFN-α response, IL-1β production, TLR signaling, NLRP3 inflammasome, and pyroptosis 417 pathways, using the Gene Ontology (GO) database; the NLR signaling pathway using the 418 Kyoto Encyclopedia of Genes and Genomes (KEGG) database; and inflammasome pathway 419 using the REACTOME database (Figure 4). These pathways were significantly enriched in 420 COVID-19 patients, supporting our findings. Importantly, the genes from the above-mentioned 421 pathways were also induced in non-COVID-19 patients, suggesting that these pathways 422 represent a general neutrophil response to inflammatory stimuli rather than a COVID-19 423 specific response.

424

### 425 Type I IFNs prime PMNs for inflammasome activation

Since PMNs from COVID-19 patients concomitantly display a strong IFN-I signature (Figure 426 427 2B) and an increased propensity for inflammasome activation, we hypothesized that IFN-I 428 could act as the priming signal for PMN inflammasomes during COVID-19. Isolated HC PMNs 429 were stimulated ex vivo with exogenous IFN-I and the well-described inflammasome priming (1<sup>st</sup> signal) and activator (2<sup>nd</sup> signal) agents LPS and nigericin, respectively <sup>34,35</sup>. After 430 431 stimulation, both priming signals induced pro-IL-1 $\beta$  (31 kDa) in the cell lysates, followed by 432 the release of active IL-1 $\beta$  (17 kDa) into the supernatant in response to nigericin (Figure 5A), 433 confirming the ability of IFN-I to prime PMNs for inflammasome activation.

434 To assess inflammasome formation in circulating neutrophils during COVID-19, PMNs from 435 HC and COVID-19 patients underwent similar stimulation assays as above, followed by IL-1β 436 measurement from supernatants by ELISA. In addition, to further assess the role of SARS-437 CoV-2 virus particles in neutrophil inflammasome activation, HC PMNs were cultured in the 438 presence of purified viruses (10 infectious units/PMN). HC PMNs responded to both LPS and 439 IFN-I by increasing their IL-1 $\beta$  secretion, which was exponentiated after exposure to nigericin 440 (Figure 5A), confirming the ability of IFN-Is to prime for inflammasome assembly in PMNs, 441 albeit less efficiently than LPS. Interestingly, COVID-19 PMNs produced less IL-1β than HC PMNs upon exogenous inflammasome activation primed by either LPS or IFN-I, while SARS-442 443 CoV-2 particles did not have any effect on PMN inflammasome activation (Figure 5B). As with 24-h cultures (Figure 3D), we did not detect any significant changes in IL-18 expression 444 445 in either HC or COVID-19 PMNs (data not shown). However, myeloperoxidase (MPO), a 446 marker of neutrophil degranulation and NETosis <sup>36</sup>, responded to nigericin indistinctively 447 between COVID-19 PMNs and HC PMNs, and therefore the observed diminished IL-1ß 448 release by COVID-19 PMNs is not due to general cellular inertia but may be specific to the ex

449 *vivo* induced inflammasome pathway. Furthermore, additional stimulation assays in the 450 presence of the NLRP3 inhibitor MCC950 (Figures 5D-E) and caspase1 inhibitor YVAD 451 (Supplementary Fig. 3A) confirmed that induced IL-1β secretion is dependent on canonical 452 NLRP3 inflammasome activation. However, unlike IL-1β (Supplementary Fig. 3B), increased 453 IL-18 secretion was not detectable even after 24-h stimulation (Supplementary Fig. 3C). 454 Furthermore, the observed residual IL-18 was not affected by inflammasome inhibitors, 455 suggesting its secretion to be unrelated to inflammasome activity in PMNs.

456 We further assessed the specificity of inflammasome activation by measuring LDH and IL-8 457 levels in the supernatants from the same cells and under the same experimental conditions as 458 shown in Figures 5D-E. The measurements of the former were done to assess inflammasome 459 mediated cell death by pyroptosis in response to nigericin, while the latter was assessed to 460 demonstrate the responsiveness of PMNs to an inflammasome unrelated inflammatory cascade. 461 As with IL-1ß secretion, COVID-19 PMNs were less responsive than HC PMNs to nigericinand LPS-mediated LDH (Figure 5F) and IL-8 (Figure 5G) release, respectively. This suggests 462 463 that COVID-19 PMNs are generally poorly responsive to inflammatory stimuli while retaining 464 the ability for degranulation and NETosis (see above).

To examine this reduced responsiveness to external inflammatory priming, we evaluated the inflammasome related gene expression following *ex vivo* stimulation with IFN-I or LPS (Figure 5H-I and Supplementary Fig. 3D-G). OAS1 gene, an interferon stimulated gene (ISG), showed significant upregulation by IFN-I in COVID-19 PMNs as compared to HC PMNs (Figure 5H), while the inflammasome related genes IL-1 $\beta$  (Figure 5I), CASP1 (Figure 5J) and NLRC5 (Figure 5K) were more efficiently induced in HC PMNs than COVID-19 PMNs. This suggests that the inflammasome defect in COVID-19 PMNs is at the transcriptional level when using

472 IFN-I as the priming factor, while high OAS1 gene expression indicates transcriptional defect473 is restricted to individual genes.

### 474 Association between *ex vivo* inflammasome activation and disease severity

475 Our analysis of the association between *ex vivo* inflammasome activation (caspase1 activity 476 and IL-1ß release) and clinical markers of disease severity, including neutrophil responses, 477 revealed intriguing links. Calprotectin is marker of neutrophil activation or death <sup>37</sup> but also potentially activates the inflammasome (<sup>38</sup>. A significant positive correlation between 478 479 calprotectin plasma levels and PMN caspase1 activity (Figure 6A-B) underscores this latter possibility and highlights the interplay between inflammation and inflammasome activation in 480 481 PMNs of COVID-19 patients. Furthermore, the negative association of PMN IL-1β levels (after 482 ex vivo stimulation) with disease severity (WHO ordinal scale, Figure 6A) and patient 483 neutrophil counts (Figure 6A, C) supports the exhaustion hypothesis, wherein PMNs from severe COVID-19 patients may be less responsive to stimuli due to prior in vivo activation. 484 485 While these findings provide intriguing insights into the complex interplay between 486 calprotectin release, caspase1 activity, and inflammasome activation in COVID-19, additional 487 research is required to further elucidate these connections.

# 488 LDGs differ from PMNs in gene expression and release of inflammasome related 489 interleukins

To assess the inflammasome related inflammatory profile of COVID-19 LDGs in comparison
to PMNs, we analyzed the differential expression of inflammasome related genes using RNAseq (Figure 7A). LDGs differed significantly from PMNs, with the most striking difference
being their increased expression of IL-18 and NLRC4, whereas PMNs displayed higher levels
of IL-1β, NLRP3 and caspases 1, 4 and 5. Single cell sequencing data from the COVID-19

immune atlas confirmed our transcriptomic results (Figure 7B), from which a detailed gene by gene analysis of the most relevant inflammasome related genes is shown (Figure 7C and Supplementary Fig. 4). Briefly, PYCARD gene coding for the ASC protein was expressed similarly in mature and immature neutrophils (Supplementary Fig. 4), confirming that both cell types have inflammasome forming capacity. However, most of the inflammasome gene expressions differed significantly and in the same manner as in our transcriptomic analysis.

501

We conducted *ex vivo* stimulation assays using LDGs isolated from COVID-19 patients, similar to the approach used for PMNs described earlier. Like PMNs, IL-1 $\beta$  secretion by LDGs was elevated in the presence of a priming signal (IFN-I or LPS), which exponentially increased when the inflammasome activation signaling molecule nigericin was added (Figure 7D). Contrary to PMNs and in line with the transcriptomics data, an increased IL-18 secretion was detected (Figure 7E). Additionally, the secretion of both ILs by LDGs was inhibited in the presence of inflammasome specific inhibitors MCC950 and YVAD (Figure 7F-G).

509 These findings suggested that the outcome of neutrophil inflammasome activation varies based 510 on cellular maturation state. To explore this further, we conducted in vitro stimulation studies using differentiated HL-60 cells, an immature neutrophil-like model <sup>39</sup>. Similar to LDGs from 511 COVID-19 patients, HL-60 displayed comparable IL-18 secretion pattern upon LPS or IFN-I 512 513 stimulation and nigericin-induced activation. Notably, their IL-1ß release was only detected 514 with LPS priming (Figures 7F-G). Furthermore, consistent with transcriptomic analysis 515 revealing an upregulation of inflammasome related genes upon differentiation (Figure 7H), the 516 capacity of HL-60 cells to secrete inflammasome related cytokines was differentiation-517 dependent (data not shown). Overall, these findings suggest that neutrophils may lose the 518 ability to secrete IL-18 during maturation, and release of neutrophil-derived IL-18 occurs

primarily in disease states associated with extensive granulopoiesis and increased immature
 granulocyte counts in the blood, like COVID-19<sup>40</sup>.

521

### 522 Neutrophils are recruited to the lungs in SARS-CoV-2 infected mice

Hamsters and human ACE2 expressing mice infected with SARS-CoV-2 develop pulmonary 523 inflammation including neutrophil recruitment 41-43. To further assess the role of neutrophils in 524 COVID-19, we utilized a recently developed SARS-CoV-2 mouse model <sup>18</sup>. This model 525 employs the MaVie strain, serially passaged in mouse lungs and causing pneumonia similar to 526 527 human COVID-19 in wild-type BALB-C mice <sup>18</sup>. Infected mice started losing weight by day 2 528 post-infection, with some mice reaching the clinical endpoint of 20% weight loss by day 4 (Supplementary Fig. 5A). Viral loads were significantly higher at 2 dpi than 4 dpi (Figure 8A), 529 and viral antigen expression, widespread at 2dpi in bronchioles and alveoli, matched this 530 531 pattern (Figure 8B and D). The extensive viral replication at 2 dpi was associated with 532 degeneration of infected epithelial cells, most prominent in the respiratory epithelium, 533 accompanied by neutrophil (Lv6G+) infiltration (Figure 8D) and a significant increase in the 534 number of neutrophils in the lungs of infected mice compared to PBS-inoculated mice (Figure 535 8C). Neutrophil numbers significantly decreased by 4dpi but remained higher than controls (Figure 8C). Detailed information on the histological and immunohistochemical features of 536 537 these mice is provided in Supplementary Table S2. Together, these findings suggest a pivotal 538 role of neutrophils in clearing the virus in SARS-CoV-2 infected mice.

539

# 540 Neutrophils from SARS-CoV-2 infected mice display IFN-I dependent caspase1 541 activation

542 We isolated neutrophils from the lungs of infected mice at 2 and 4 dpi, as well as from non-543 infected mice (inoculated with PBS) for transcriptomic analysis by RNA-seq (Exp 1). PCA

544 showed distinct differences between neutrophils from infected and non-infected mice, with 545 slight variation between the 2 and 4 dpi time points (Figure 9A). These differences were 546 reflected in many DEGs, including several IFN-I responsive and inflammasome related genes, 547 which showed strong upregulation at 2 dpi with slightly lower but still significantly elevated 548 levels at 4 dpi, compared to non-infected mice (highlighted in the DEG heatmap; Figure 9B). 549 The volcano plot (Figure 9C) provided a comprehensive view of the DEG pattern between 550 neutrophils from SARS-CoV-2 infected and mock-infected mice. In addition to confirming the 551 upregulation of IFN-I responsive and inflammasome related genes observed in the heatmap, 552 the plot revealed a broader transcriptional response to viral infection with several additional 553 DEG.

Next, we investigated if neutrophils from SARS-CoV-2 infected mice showed increased 554 555 inflammasome formation, similar to PMNs from COVID-19 patients. Neutrophils from 556 infected mice, harvested at 2 and 4 dpi, displayed increased caspase1 activity upon nigericin 557 stimulation, compared to neutrophils from non-infected mice (Exp 2; Figure 9D). To assess the 558 role of IFN-I, we inoculated mice with an IFN-I blocking anti-IFNAR monoclonal antibody or 559 an isotype control antibody post-infection (Exp 3). Remarkably, neutrophils from anti-IFNAR 560 treated mice showed diminished nigericin-induced caspase1 activity (Figure 9E). Furthermore, 561 caspase1 and IL-1 $\beta$  gene expressions were lower in anti-IFNAR treated than isotype treated 562 mice (Figure 9F-G). Taken together, IFN-I appears to be responsible for the increased caspase1 563 activity in neutrophils of infected mice.

Histology of isotype-treated mice and anti-IFNAR treated mice lungs showed comparable features (Supplementary Fig. 5C) as infections without antibody (Exp 1; Figure 8B-D). Regardless of treatment, some neutrophils in infected mice displayed degeneration and NETosis evidenced by histone H3 staining (Supplementary Fig. 5C; Supplementary Table S2), and viral loads remained consistent between anti-IFNAR or IgG1 isotype control treated mice

- 569 (Supplementary Fig. 5B). Taken together, blocking IFN-I signaling did not alter virus
- 570 replication, virus-induced pathological changes, or early neutrophil recruitment following
- 571 infection.

## 572 **Discussion**

Neutrophils, the largest cell population of the host immune system, are rapidly recruited to sites of infection and play an important role in orchestrating an early immune response <sup>44,45</sup>. The relevance of neutrophils in viral infections became increasingly apparent during the COVID-19 pandemic, as they have been shown to be key mediators of the observed pathological processes <sup>46</sup>.

578 This study sheds light on the potential involvement of the inflammasome pathway in COVID-579 19, particularly by demonstrating its activation in neutrophils during SARS-CoV-2 infection. 580 Our investigation of the inflammatory profile of neutrophils as the dominant population of 581 peripheral blood polymorphonuclear cells (PMNs) revealed an increased ability of neutrophils 582 from severe COVID-19 patients for inflammasome assembly as evidenced by their 583 transcriptional profile, spontaneous release of IL-1 $\beta$ , and elevated caspase1 activity. These 584 findings are consistent with previous reports indicating activation of the NLRP3 inflammasome and ASC specks in circulating neutrophils during acute COVID-19<sup>14,16</sup>. Furthermore, despite 585 showing increased caspase1 activity, neutrophils from COVID-19 patients exhibited 586 587 diminished soluble IL-1ß production upon exogenous activation of the NLRP3 inflammasome pathway compared to healthy controls, which suggests that this pathway is "exhausted" due to 588 589 prior activation during the disease. Mechanistically, our findings show that IFN-I, elevated in 590 COVID-19 patients <sup>47,48</sup>, can prime inflammasome formation in neutrophils. Transcriptomic 591 analyses revealed that circulating neutrophils during severe COVID-19 show increased 592 expression of IFN-responsive genes, suggesting inflammasome priming by IFN-I also in vivo 593 during COVID-19<sup>49</sup>. Furthermore, the study found that immature neutrophils, which are 594 prevalent in low-density granulocyte fraction (LDGs), exhibit unique inflammasome gene 595 expression and outcomes compared to mature neutrophils (PMNs). LDGs release IL-18 and

upregulate distinct inflammasome related genes but lack the IFN-I signature seen in PMNs
during COVID-19, indicating lower responsiveness to IFN-I, and supported by less efficient
IFN-I mediated inflammasome priming of LDGs *ex vivo*.

599 SARS-CoV-2 infected mice also showed increased neutrophil caspase1 activity, reversible by 600 an IFN-I receptor (IFNAR) blocking antibody. Transcriptional analysis revealed a robust IFN-601 I signature and elevated expression of inflammasome genes encoding for caspase1 and IL-1 $\beta$ 602 in neutrophils of infected mice, which were also inhibited by blocking IFNAR signaling, 603 suggesting that IFN-I may also prime for inflammasome activation in mice. Notably, the anti-604 IFNAR treatment did not affect neutrophil recruitment or NETosis, which is consistent with 605 another COVID-19 model using transgenic human ACE2, where IFNAR knockout inhibited recruitment of monocytes and lymphocytes, but not neutrophils, to infected lungs <sup>50</sup>. 606

607 Inflammasomes were initially studied in macrophages, revealing a plethora of molecular mechanisms regulating inflammasome assembly <sup>51</sup>. Macrophage inflammasome activation has 608 609 emerged as a major factor also in COVID-19<sup>17</sup>. Interestingly, macrophage inflammasome 610 activation was recognized to be IFN-I mediated in an experimental rhesus macaque COVID-19 model 52. However, due to the abundance of neutrophils compared with cells of 611 monocyte/macrophage lineage <sup>53,54</sup>, the significance of neutrophil inflammasomes in COVID-612 613 19 is likely underestimated. Our results highlight inflammasomes as an additional important 614 inflammatory mechanism in neutrophils <sup>14</sup>, complementing their role in phagocytosis, reactive oxygen species generation, degranulation, and NETosis <sup>32</sup>. 615

616 SARS-CoV-2 can directly activate inflammasomes in cells of the monocyte/macrophage 617 lineage <sup>17</sup>. Our study investigated whether SARS-CoV-2 can provide the first or second signal 618 for inflammasome activation in neutrophils. However, we found no evidence of direct virus-619 induced inflammasome activation in neutrophils. The difference between macrophages and

620 neutrophils in their susceptibility to SARS-CoV-2 could depend on many factors. Both cell 621 types express ACE2, the receptor for SARS-CoV-2, but may differ in ACE2 expression levels <sup>55</sup>. Furthermore, the intracellular environment of macrophages is better suited for viral 622 replication <sup>56</sup>, while neutrophils focus on phagocytosis and antimicrobial responses <sup>32,57</sup>. 623 Additionally, pathogen opsonization can trigger inflammasomes in macrophages <sup>58</sup> but is not a 624 625 primary function of neutrophils. Therefore, our findings suggest neutrophil inflammasome 626 activation in response to SARS-CoV-2 likely results from interactions with infected and/or 627 dving cells in the lungs, rather than direct virus activation. To note, whether SARS-CoV-2 can 628 induce neutrophil inflammasomes through immune complex-mediated mechanisms, as seen in monocytes/macrophages <sup>17</sup> remains to be determined. 629

In this study, we demonstrated IFN-I as the first signal for NLRP3 inflammasome activation in neutrophils. While prior research has explored IFN-inflammasome crosstalk <sup>59</sup>, priming capacity of IFN-I remained unclear. While IFN-I promotes inflammasomes in epithelial cells <sup>60</sup> it can also dampen IL-1 $\beta$  in macrophages <sup>61</sup>. Plausibly, initial IFN-I exposure may upregulate inflammasome genes, whereas prolonged activity could hinder IFN-I signaling via "negative feedback" loop, in line with our findings of inflammasome exhaustion in circulating neutrophils of severe COVID-19 patients.

Our study also unveiled distinct gene profiles in LDGs and PMNs from severe COVID-19 patients. LDGs exhibited upregulation of genes related to DNA replication and cell cycle, indicating immaturity, and confirming our prior findings <sup>7</sup>. Conversely, PMNs displayed heightened NLR signaling, suggesting a robust response to pathogens. While our study compared PMNs and LDGs, and the COVID-19 Immune Atlas single cell analysis represented a broader classification of mature and immature neutrophils, the alignment of our results with the atlas provides further support for the distinct characteristics of these two neutrophil

populations in severe COVID-19. Notably, IL-18 gene expression and secretion after *ex vivo*stimulation were higher in LDGs than PMNs. To note, PMN's lack of IL-18 secretion is not
due to lack of protein, as they constitutively express significant amounts intracellularly <sup>62</sup>. This
indicates a similarity between LDGs and monocytes/macrophages in inflammasome mediated
IL-18 processing, possibly lost during neutrophil maturation.

649

650 The present study has some limitations worth discussing. Firstly, the relatively small human 651 sample size may limit the generalizability of the findings. While RNA-seq provided valuable 652 insights into gene expression profiles of PMNs and LDGs, we did not perform functional 653 validation of the identified pathways in this study. Regarding our experimental SARS-CoV-2 654 infected model, the high virus input might trigger robust immune responses that differ from 655 typical human infections, and the short-lived virus replication in the applied model does not 656 capture the effect of prolonged antigen exposure or the complex inflammatory milieu seen in 657 human cases. The prominent role of neutrophils in the immune response to viral infections is widely recognized <sup>44,45</sup> and it would be valuable to compare these findings to neutrophil 658 659 responses in other viral respiratory infections.

660

Taken together, our findings provide valuable insights into neutrophil involvement in COVID-661 662 19 and possibly other viral respiratory infections. However, further research is needed to fully 663 grasp the role of neutrophil inflammasomes in COVID-19 pathogenesis. This increased 664 understanding may facilitate the development of targeted treatment approaches for COVID-19. The next steps involve validating the pathways and genes identified as potential therapeutic 665 666 targets and assessing their COVID-19 specificity. Prospectively, these strategies could be extended to address upcoming respiratory virus pandemics, where neutrophils and 667 668 inflammasomes provide major pathogenic contributions.

### 669 **Contributors**

- 670 L.E.C.: conceptualization, data curation, formal analysis, investigation, software, validation,
- 671 visualization, writing- original draft; S.T.J.: investigation, writing review & editing; Sa.M.:
- 672 investigation; Si.M.: investigation; R.K.: resources; L.K.; investigation, writing review &
- 673 editing; Ta.S.: resources; J-P.P.: resources; Anu.K.: funding acquisition, resources, writing –
- 674 review & editing; E.K.: supervision, writing review & editing; H.L.: resources; P.M.:
- 675 resources, writing review & editing; Anj.K.: investigation, methodology, supervision,
- validation, visualization, writing review & editing; O.V.: funding acquisition, resources;
- 677 To.S.: conceptualization, data curation, formal analysis, funding acquisition, investigation,
- 678 methodology, project administration, supervision, validation, writing original draft.

679

## 680 Declaration of Competing Interest

All authors declare no financial competing interests related to the study.

682

### 683 Acknowledgements

684

This work was financed by grants by the Academy of Finland to To.S. (321809), Anu.K. (336439 and 335527); grants by the Helsinki University Hospital funds to O.V. (TYH 2021343); EU Horizon 2020 programme VEO (874735) to O.V.; Finnish governmental subsidy for Health Science Research (TYH 2021315) to Anu.K.; Paulon Säätiö to L.E.C.; Suomen Lääketieteen Säätiö to L.E.C.; Jane and Aatos Erkko foundation to O.V. The funders had no role in study design, data collection and analysis, nor decision to publish, or preparation of the manuscript.

692

- 693 RNA isolation, library preparations and RNA sequencing was performed at the Institute for
- 694 Molecular Medicine Finland FIMM, Genomics unit supported by HiLIFE and Biocenter
- 695 Finland. The authors also thank M. Utriainen for expert technical assistance.

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 696 **References**

### 697

698 1 Wilk AJ, Lee MJ, Wei B, et al. Multi-omic profiling reveals widespread 699 dysregulation of innate immunity and hematopoiesis in COVID-19. Journal of Experimental Medicine 2021; 218. DOI:10.1084/jem.20210582. 700 701 2 Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response 702 to SARS-CoV-2 Drives Development of COVID-19. Cell 2020; 181: 1036-703 1045.e9. 704 3 Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients... 705 706 4 Domizio J Di, Gulen MF, Saidoune F, et al. The cGAS-STING pathway drives 707 type I IFN immunopathology in COVID-19. Nature 2022; 603: 145-51. 708 5 Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. Targeting potential drivers of 709 COVID-19: Neutrophil extracellular traps. Journal of Experimental Medicine. 710 2020; 217. DOI:10.1084/jem.20200652. 711 6 Radermecker C, Detrembleur N, Guiot J, et al. Neutrophil extracellular traps 712 infiltrate the lung airway, interstitial, and vascular compartments in severe 713 COVID-19. Journal of Experimental Medicine 2020; 217. DOI:10.1084/jem.20201012. 714 7 715 Cabrera LE, Pekkarinen PT, Alander M, et al. Characterization of low-density 716 granulocytes in COVID-19. PLoS Pathog 2021; 17. 717 DOI:10.1371/journal.ppat.1009721. 718 8 LaSalle TJ, Gonye ALK, Freeman SS, et al. Longitudinal characterization of 719 circulating neutrophils uncovers phenotypes associated with severity in 720 hospitalized COVID-19 patients. Cell Rep Med 2022; 3. DOI:10.1016/j.xcrm.2022.100779. 721 9 Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 Is Marked 722 723 by a Dysregulated Myeloid Cell Compartment. Cell 2020; 182: 1419-1440.e23. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of 724 10 granulocytes and lymphocytes in bone marrow. Journal of Experimental 725 726 Medicine 2005; 201: 1771-80. Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. 727 11 728 JCI Insight 2020; 5. DOI:10.1172/jci.insight.138999. 729 12 Potere N, Giuseppe M, Buono D, et al. Interleukin-1 and the NLRP3 730 inflammasome in COVID-19: Pathogenetic and therapeutic implications. 2022. 731 DOI:10.1016/j. Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR 732 13 733 inflammasome signaling. Curr Opin Struct Biol. 2014; 29: 17-25. 734 14 Aymonnier K, Ng J, Fredenburgh LE, et al. Inflammasome activation in 735 neutrophils of patients with severe COVID-19. Blood Adv 2022; 6: 2001-13. 736 15 Courjon J, Dufies O, Robert A, et al. Heterogeneous NLRP3 inflammasome 737 signature in circulating myeloid cells as a biomarker of COVID-19 severity. 738 Blood Adv 2021; 5: 1523-34. 739 16 Leal VNC, Andrade MMS, Teixeira FME, et al. Severe COVID-19 patients 740 show a dysregulation of the NLRP3 inflammasome in circulating neutrophils. 741 Scand J Immunol 2022. DOI:10.1111/sji.13247. 742 17 Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in infected 743 macrophages drives COVID-19 pathology. Nature 2022; 606: 585-93.

| 744 | 18 | Gawish R, Starkl P, Pimenov L, et al. ACE2 is the critical in vivo receptor for           |
|-----|----|---|
| 745 |    | SARS-CoV-2 in a novel COVID-19 mouse model with TNF-and IFNy-driven                       |
| 746 |    | immunopathology. <i>Elife</i> 2022; <b>11</b> . DOI:10.7554/eLife.74623.                  |
| 747 | 19 | Rusanen J, Kareinen L, Szirovicza L, et al. A Generic, Scalable, and Rapid                |
| 748 |    | Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen                   |
| 749 |    | Detection-SARS-CoV-2 as a Proof of Concept. 2021. DOI:10.1128/mBio.                       |
| 750 | 20 | Kallio MA, Tuimala JT, Hupponen T, et al. Chipster: User-friendly analysis                |
| 751 |    | software for microarray and other high-throughput data. BMC Genomics 2011;                |
| 752 |    | <b>12</b> . DOI:10.1186/1471-2164-12-507.   |
| 753 | 21 | Liu P, Ewald J, Pang Z, et al. ExpressAnalyst: A unified platform for RNA-                |
| 754 |    | sequencing analysis in non-model species. Nat Commun 2023; 14: 2995.                      |
| 755 | 22 | Emig D, Salomonis N, Baumbach J, Lengauer T, Conklin BR, Albrecht M.                      |
| 756 |    | AltAnalyze and DomainGraph: Analyzing and visualizing exon expression data.               |
| 757 |    | Nucleic Acids Res 2010; <b>38</b> . DOI:10.1093/nar/gkq405.                               |
| 758 | 23 | Babicki S, Arndt D, Marcu A, et al. Heatmapper: web-enabled heat mapping for              |
| 759 |    | all. Nucleic Acids Res 2016; 44: W147–53.   |
| 760 | 24 | Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling cell type abundance                   |
| 761 |    | and expression in bulk tissues with CIBERSORTx. In: Methods in Molecular                  |
| 762 |    | Biology. Humana Press Inc., 2020: 135–57.   |
| 763 | 25 | Li Y, He Y, Liang Z, et al. Alterations of specific chromatin conformation                |
| 764 |    | affect ATRA-induced leukemia cell differentiation. Cell Death Dis 2018; 9.                |
| 765 |    | DOI:10.1038/s41419-017-0173-6.  |
| 766 | 26 | CZ CELLxGENE Discover. Chan Zuckerberg Initiative.  |
| 767 |    | https://cellxgene.cziscience.com/.  |
| 768 | 27 | Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus                  |
| 769 |    | (2019-nCoV) by real-time RT-PCR. Eurosurveillance 2020; 25.                               |
| 770 |    | DOI:10.2807/1560-7917.ES.2020.25.3.2000045.   |
| 771 | 28 | Dagotto G, Mercado NB, Martinez DR, et al. Comparison of Subgenomic and                   |
| 772 |    | Total RNA in SARS-CoV-2-Challenged Rhesus Macaques. 2021.                                 |
| 773 |    | DOI:10.1128/JVI.  |
| 774 | 29 | Kant R, Kareinen L, Smura T, et al. Common laboratory mice are susceptible to             |
| 775 |    | infection with the SARS-CoV-2 beta variant. Viruses 2021; 13.                             |
| 776 |    | DOI:10.3390/v13112263.  |
| 777 | 30 | Schmid AS, Hemmerle T, Pretto F, Kipar A, Neri D. Antibody-based targeted                 |
| 778 |    | delivery of interleukin-4 synergizes with dexamethasone for the reduction of              |
| 779 |    | inflammation in arthritis. <i>Rheumatology (United Kingdom)</i> 2018; <b>57</b> : 748–55. |
| 780 | 31 | Seehusen F, Clark JJ, Sharma P, et al. Neuroinvasion and Neurotropism by                  |
| 781 |    | SARS-CoV-2 Variants in the K18-hACE2 Mouse. Viruses 2022; 14.                             |
| 782 |    | DOI:10.3390/v14051020.  |
| 783 | 32 | Rosales C. Neutrophil: A cell with many roles in inflammation or several cell             |
| 784 |    | types? Front Physiol. 2018; <b>9</b> . DOI:10.3389/fphys.2018.00113.                      |
| 785 | 33 | Walle L Vande, Lamkanfi M. Inflammasomes: Caspase-1-activating platforms                  |
| 786 |    | with critical roles in host defense. Front Microbiol 2011; 2.                             |
| 787 |    | DOI:10.3389/fmicb.2011.00003.   |
| 788 | 34 | Perregaux D, Gabel CA. Interleukin-1 $\beta$ maturation and release in response to        |
| 789 |    | ATP and nigericin. Evidence that potassium depletion mediated by these agents             |
| 790 |    | is a necessary and common feature of their activity. Journal of Biological                |
| 791 |    | <i>Chemistry</i> 1994; <b>269</b> : 15195–203.  |

| 792<br>793<br>794 | 35             | Gong YN, Wang X, Wang J, <i>et al.</i> Chemical probing reveals insights into the signaling mechanism of inflammasome activation. <i>Cell Res</i> 2010; <b>20</b> : 1289–305 |
|-------------------|----------------|--|
| 795<br>796        | 36             | Grigorieva D V., Gorudko I V., Sokolov A V., <i>et al.</i> Myeloperoxidase<br>stimulates neutrophil degranulation <i>Bull Exp Biol Med</i> 2016: <b>161</b> : 495–500        |
| 797<br>798        | 37             | Silvin A, Chapuis N, Dunsmore G, <i>et al.</i> Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19. <i>Cell</i> 2020:             |
| 799               |                | <b>182</b> : 1401-1418.e18.  |
| 800               | 38             | Simard JC, Cesaro A, Chapeton-Montes J, et al. S100A8 and S100A9 induce  |
| 801               |                | cytokine expression and regulate the NLRP3 inflammasome via ROS-dependent  |
| 802               |                | activation of NF-κB(1.). <i>PLoS One</i> 2013; <b>8</b> .  |
| 803               |                | DOI:10.1371/journal.pone.0072138.  |
| 804               | 39             | Jacob C, Leport M, Szilagyi C, Allen JM, Bertrand C, Lagente V. DMSO-  |
| 805               |                | treated HL60 cells: a model of neutrophil-like cells mainly expressing PDE4B   |
| 806               | 40             | subtype. www.elsevier.com/locate/intimp.   |
| 808               | 40             | lymphohisticcytosis like hyperinflammation and enhanced myelonoiesis   |
| 809               |                | Journal of Allergy and Clinical Immunology 2022: <b>150</b> : 1154–67  |
| 810               | 41             | Xue Y. Yang D. Vogel P. <i>et al.</i> Cardiopulmonary Injury in the Syrian Hamster   |
| 811               |                | Model of COVID-19. <i>Viruses</i> 2022; <b>14</b> . DOI:10.3390/v14071403.   |
| 812               | 42             | Vargas F, Castanheira S, Nguyen R, et al. Intravital imaging of 3 different  |
| 813               |                | microvascular beds in SARS-CoV-2-infected mice.  |
| 814               |                | DOI:10.1182/bloodadvances.2022009430/2057344/bloodadvances.2022009430.   |
| 815               |                | pdf.   |
| 816               | 43             | Winkler ES, Bailey AL, Kafai NM, et al. SARS-CoV-2 infection of human  |
| 817               |                | ACE2-transgenic mice causes severe lung inflammation and impaired function.  |
| 818               |                | <i>Nat Immunol</i> 2020; <b>21</b> : 1327–35.  |
| 819               | 44             | Zhang Y, Wang Q, Mackay CR, Ng LG, Kwok I. Neutrophil subsets and their  |
| 820               |                | differential roles in viral respiratory diseases. J Leukoc Biol. 2022; 111: 1159–  |
| 822               | 15             | 75.<br>Camp I.V. Jonsson CB. A role for neutrophils in viral respiratory disease. Front  |
| 823               | <del>4</del> 5 | Immunol. 2017; <b>8</b> . DOI:10.3389/fimmu.2017.00550.  |
| 824               | 46             | McKenna E, Wubben R, Isaza-Correa JM, et al. Neutrophils in COVID-19: Not  |
| 825               |                | Innocent Bystanders. Front Immunol. 2022; 13.  |
| 826               |                | DOI:10.3389/fimmu.2022.864387.   |
| 827               | 47             | Lee JS, Park S, Jeong HW, et al. Immunophenotyping of covid-19 and influenza   |
| 828               |                | highlights the role of type i interferons in development of severe covid-19. Sci   |
| 829               | 10             | <i>Immunol</i> 2020; <b>5</b> . DOI:10.1126/sciimmunol.abd1554.  |
| 830               | 48             | Sinha S, Rosin NL, Arora R, <i>et al.</i> Dexamethasone modulates immature   |
| 831               |                | neutrophils and interferon programming in severe COVID-19. <i>Nat Mea</i> 2022;  |
| 832<br>833        | 40             | 20. 201-11.<br>Takeuchi O. Akira S. Pattern Peccanition Pecentors and Inflammation Call  |
| 834               | 47             | 2010 · <b>140</b> · 805–20   |
| 835               | 50             | Israelow B. Song E. Mao T. <i>et al.</i> Mouse model of SARS-CoV-2 reveals   |
| 836               |                | inflammatory role of type i interferon signaling. <i>Journal of Experimental</i>   |
| 837               |                | Medicine 2020; 217. DOI:10.1084/JEM.20201241.  |
| 838               | 51             | Broz P, Dixit VM. Inflammasomes: Mechanism of assembly, regulation and   |
| 839               |                | signalling. Nat Rev Immunol. 2016; <b>16</b> : 407–20.   |

| 840 | 52 | Hoang TN, Viox EG, Upadhyay AA, et al. Modulation of type I interferon                |
|-----|----|---|
| 841 |    | responses potently inhibits SARS-CoV-2 replication and inflammation in rhesus         |
| 842 |    | macaques. DOI:10.1101/2022.10.21.512606.  |
| 843 | 53 | Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological           |
| 844 |    | misfiring in severe COVID-19. Nature 2020; 584: 463–9.                                |
| 845 | 54 | Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019        |
| 846 |    | novel coronavirus in Wuhan, China. The Lancet 2020; 395: 497–506.                     |
| 847 | 55 | Song X, Hu W, Yu H, et al. Little to no expression of angiotensin-converting          |
| 848 |    | enzyme-2 on most human peripheral blood immune cells but highly expressed             |
| 849 |    | on tissue macrophages. Cytometry Part A 2020; published online Feb 1.                 |
| 850 |    | DOI:10.1002/cyto.a.24285.   |
| 851 | 56 | Nikitina E, Larionova I, Choinzonov E, Kzhyshkowska J. Monocytes and                  |
| 852 |    | macrophages as viral targets and reservoirs. Int J Mol Sci. 2018; 19.                 |
| 853 |    | DOI:10.3390/ijms19092821.   |
| 854 | 57 | Patel AA, Ginhoux F, Yona S. Monocytes, macrophages, dendritic cells and              |
| 855 |    | neutrophils: an update on lifespan kinetics in health and disease. Immunology.        |
| 856 |    | 2021; <b>163</b> : 250–61.  |
| 857 | 58 | Zhou J, Ludlow LE, Hasang W, Rogerson SJ, Jaworowski A. Opsonization of               |
| 858 |    | malaria-infected erythrocytes activates the inflammasome and enhances                 |
| 859 |    | inflammatory cytokine secretion by human macrophages. Malar J 2012; 11.               |
| 860 |    | DOI:10.1186/1475-2875-11-343.   |
| 861 | 59 | Labzin LI, Lauterbach MAR, Latz E. Interferons and inflammasomes:                     |
| 862 |    | Cooperation and counterregulation in disease. Journal of Allergy and Clinical         |
| 863 |    | Immunology. 2016; <b>138</b> : 37–46.   |
| 864 | 60 | Pothlichet J, Meunier I, Davis BK, et al. Type I IFN Triggers RIG-                    |
| 865 |    | I/TLR3/NLRP3-dependent Inflammasome Activation in Influenza A Virus                   |
| 866 |    | Infected Cells. <i>PLoS Pathog</i> 2013; <b>9</b> . DOI:10.1371/journal.ppat.1003256. |
| 867 | 61 | Kopitar-Jerala N. The role of interferons in inflammation and inflammasome            |
| 868 |    | activation. Front Immunol. 2017; 8. DOI:10.3389/fimmu.2017.00873.                     |
| 869 | 62 | Robertson SE, Young JD, Kitson S, et al. Expression and alternative processing        |
| 870 |    | of IL-18 in human neutrophils. Eur J Immunol 2006; 36: 722–31.                        |
| 871 | 63 | Rubio-Rivas M, Mora-Luján JM, Formiga F, et al. WHO Ordinal Scale and                 |
| 872 |    | Inflammation Risk Categories in COVID-19. Comparative Study of the Severity           |
| 873 |    | Scales. J Gen Intern Med 2022; 37: 1980–7.  |
| 874 |    |   |
| 875 |    |   |

### 876 **Figure legends**

877 878

Figure 1. Comparison of gene expression in granulocyte populations of COVID-19 patients using 879 **RNA-seq analysis.** (A) Principal component analysis (PCA) of the RNA-seq samples (n = 7 for HC)880 PMNs, n = 19 for COVID-19 PMNs (n = 11 and 8 for severe and mild, respectively), n = 6 for severe 881 COVID-19 LDGs). (B) Ridgeline diagrams depicting the top 10 enriched signal pathways from the genes 882 differentially expressed by LDGs versus PMNs during severe COVID-19, including an overrepresentation 883 analysis (ORA) using KEGG database and gene-set enrichment analysis (GSEA) according to Reactome 884 database. Both enrichment analyses were made using ExpressAnalyst and are sorted by P-value, obtained 885 from Welch's t-test. (C) Heatmap of the top 95 differentially expressed genes between PMNs from healthy 886 controls, mild and severe COVID-19, as well as LDGs from severe disease, identified by unsupervised 887 ICGS analysis based on correlation, using AltAnalyze software. 888

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 889 Figure 2. Increased IFN-I related gene expression in mature COVID-19 neutrophils.

(A) Deconvoluted RNA-seq data. The cellular composition in isolated PMN and LDG fractions was
 estimated using CIBERSORTx through the identification of cell populations based on RNA-seq. The bar
 plots in the figure represent the cell composition of each RNA-seq sample, offering insights on sample
 purity.

(B) Heatmap of differentially expressed IFN-related genes in COVID-19 PMNs and LDGs as compared to HC PMNs. RNA sequencing was performed on purified PMNs from healthy controls, mild COVID-19 and severe COVID-19, as well as severe COVID-19 LDGs. The heatmap was reduced to include only the samples with the highest purity for their cell type, determined by a cell fraction over 0.8 of mature or immature neutrophils for PMNs and LDGs, respectively, as identified by CIBERSORTx. The heatmap was clustered by complete linkage and ordered by Spearman's rank. n = 13 COVID-19 PMNs (7 severe, 6 mild), n = 4 severe COVID-19 LDGs and n = 5 HC PMNs.

901

| 902 | Figure 3. Inflammasome related gene expression and cytokine secretion in PMNs during severe                |
|-----|--|
| 903 | COVID-19. (A-B) Ridgeline diagrams of overrepresentation analyses (ORA) according to Reactome and          |
| 904 | KEGG databases, depicting the top 10 enriched signaling pathways in PMNs during severe COVID-19            |
| 905 | compared to (A) healthy controls and (B) mild COVID-19. (C) IL-1β and (D) IL-18 levels in 24-h cell        |
| 906 | culture supernatants from COVID-19 (n = 11 for IL-1 $\beta$ and 9 for IL-18) and HC PMNs (n =6 for both).  |
| 907 | (E) IL-1 $\beta$ and (F) IL-18 levels in 24-h cell culture supernatant from PMNs exposed or non-exposed to |
| 908 | purified SARS-CoV-2 viral particles (10 virus particles / PMN) ( $n = 3$ ). (G) Caspase1 activity in PMNs  |
| 909 | following a 2-h stimulation with nigericin or purified SARS-CoV-2 viral particles (10 virus particles /    |
| 910 | PMN). For HC PMNs, $n = 9$ for mock and nigericin and $n = 6$ for SARS-CoV-2 exposure. For COVID-          |
| 911 | 19 PMNs, $n = 12$ for mock and nigericin and $n = 9$ for SARS-CoV-2 exposure. *p < 0.05 and **p < 0.01.    |
| 912 | Data presented as mean $\pm$ SD. Tukey's multiple comparisons test for mixed-effect analysis was applied   |
| 913 | for (G), meanwhile P values for (C-F) were calculated with the Mann-Whitney U-test.                        |
| 914 |  |

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in pernetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 915 Figure 4. Comparative neutrophil transcriptomics of COVID-19 and non-COVID-19 patients.

916 Bar graphs represent the activation levels of selected pathways and processes as identified by neutrophil 917 transcriptomics. The analysis includes IFN- $\alpha$  responses, IL-1 $\beta$  production, TLR signaling, NLRP3 918 inflammasomes, and pyroptosis as determined through the Gene Ontology (GO) database. The NOD-like 919 receptor signaling pathway was investigated using the Kyoto Encyclopedia of Genes and Genomes 920 (KEGG) database, and the inflammasome pathway was explored via the REACTOME database. The 921 graphs compare the activation levels of these pathways in healthy controls (HC), non-COVID patients 922 with similar symptoms (COVID-19 negative), and COVID-19 positive individuals. Statistical significance 923 is denoted as follows: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*p < 0.0001. P values were calculated with 924 Kruskall-Wallis test. 925

| 926 | Figure 5. IFN-I primes inflammasome activation while COVID-19 PMNs show defective   |
|-----|---|
| 927 | inflammasome responses ex vivo. Isolated HC or COVID-19 PMNs were non-stimulated or stimulated  |
| 928 | 4h with IFN-I (combination of $2.7*10^4$ IU/ml IFN- $\alpha$ and IFN- $\beta$ ) or 20 ng/ml LPS (1 <sup>st</sup> signal), followed by |
| 929 | 4h with 2.5 µM nigericin or purified SARS-CoV-2 (10:1 virus/PMNs) (2 <sup>nd</sup> signal). Then, (A) western blot                    |
| 930 | of pro-IL-1β (31 kD) and active IL-1β (17 kD) was performed from HC PMNs supernatant and cell   |
| 931 | lysates, (B) IL-1 $\beta$ (n = 5 HC PMN and 9 COVID-19 PMN) and (C) MPO (n = 5 HC PMN and 9 COVID-                                    |
| 932 | 19 PMN) were measured from supernatants by ELISA. (D-E) Effect of inflammasome inhibitor MCC950                                       |
| 933 | $(2 \mu g/m)$ , added simultaneously with nigericin) on IL-1 $\beta$ secretion in HC ( <b>D</b> ) and severe COVID-19 PMN             |
| 934 | (E) supernatant ( $n = 3$ ). (F) LDH and (G) IL-8 in HC and severe COVID-19 PMN supernatants ( $n = 3$ ).                             |
| 935 | (H-K) RT-qPCR of selected mRNAs in IFN-I or LPS-primed HC and COVID-19 PMNs (n = 6-8 HC   |
| 936 | PMN and 7-10 COVID-19 PMN). *p < 0.05, **p < 0.01, ***p < 0.001, **** p < 0.0001; n = 2-4. Data                                       |
| 937 | were presented as mean $\pm$ SD. P values calculated with Kruskall-Wallis test for the comparison between                             |
| 938 | treatments by group (HC or COVID-19 PMNs), and Mann-Whitney test for the comparison between HC  |
| 939 | and COVID-19 PMNs by individual treatment for (B-G), and Two-way ANOVA Tukey's multiple   |
| 940 | comparisons test for (B, H-K). Data presented as mean $\pm$ SD.   |
| 941 |   |

| 942 | Figure 6. Correlation analysis between clinical parameters and ex vivo PMN inflammasome                                 |
|-----|---|
| 943 | activation. (A) Spearman's correlation matrix depicting the relationships among clinical parameters and                 |
| 944 | results of <i>ex vivo</i> experimentation. For the WHO ordinal scale, the baseline parameters were used. ( <b>B-C</b> ) |
| 945 | Linear regression analysis demonstrating the associations between: ( <b>B</b> ) Positive association between PMN        |
| 946 | Caspase1 activity, measured after ex vivo nigericin stimulation, and the levels of Calprotectin in the                  |
| 947 | matched patient's peripheral blood; (C) Negative association between ex vivo stimulated PMN IL-1β                       |
| 948 | levels (LPS+Nig) and the blood neutrophil count in matched patients at the time of sampling (n=12).                     |
| 949 | LOS = length of stay. WHO = World Health Organization. Min = minimum. Casp1 = caspase1. LPS or                          |
| 950 | IFN + nig = lipopolysaccharide or type I interferon + nigericin ex vivo stimulation.                                    |
| 951 |   |

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

| 952        | Figure 7. Immature neutrophils express IL-18 in response to inflammasome activation. |
|------------|--|
| <i>,,,</i> | inguie // initiature neutrophils enpress in response to initiatinitasonie activation |

(A) Heatmap depicting selected differentially expressed inflammasome related genes from RNA sequencing performed in PMNs from HC, mild and severe COVID-19, as well as severe COVID-19
(b) LDGs. Only the samples with the highest purity, determined by a cell fraction over 0.8 of mature or immature neutrophils for PMN and LDG, respectively, (identified by CIBERSORTx) are included. The heatmap was clustered by complete linkage and ordered by Spearman's rank.

(B) UMAP analysis of the COVID-19 Immune Atlas, which integrates 5 public COVID-19 PBMC singlecell transcriptomics datasets, created using CELLxGENE. (Top) UMAP showing the clustering of CD16<sup>+</sup> cells (mature, FCGR3B expressing cells) and CD66b<sup>+</sup> cells (immature, CEACAM8 expressing cells).
Each dot represents a single cell colored according to the expression level of a selected gene. The color scale ranges from green (low expression) to purple (high expression). (Bottom) Pie chart summarizing the percentage of mature (black) and immature (blue) cells in the dataset.

964 (C) The fraction of mature and immature neutrophils cells expressing inflammasome related genes
965 identified in Figure 7B are shown in a bar graph. For each gene, the proportion of expressing cells is
966 shown in light blue, while the proportion of negative or not-expressing cells is shown in gray. Zoomed-in
967 bar graph depicts the proportion of mature and immature cells expressing each gene.

968(**D-G**) Isolated COVID-19 LDGs or HL-60 cells (differentiated for 5 days with 1% DMSO) were non-<br/>stimulated or stimulated 4h with IFN-I or LPS (1<sup>st</sup> signal), followed by 4h with nigericin (2<sup>nd</sup> signal) in<br/>the presence or absence of inflammasome inhibitors MCC950 or YVAD as previously. Secretion of (D,<br/>F) IL-1 $\beta$  and (E, G) IL-18 were measured from the supernatants by ELISA (n = 2 for LDGs and 3-5 for<br/>HL-60).973\*p < 0.05 and \*\*p < 0.01. P values calculated with Kruskal-Wallis test. Data presented as mean ± SD.</td>

973 \*p < 0.05 and \*\*p < 0.01. P values calculated with Kruskal-Wallis test. Data presented as mean ± SD.</li>
 974 (H) Volcano plot of differentiated vs undifferentiated HL-60 cells gene expression from GSE93996, w

975

976

(H) Volcano plot of differentiated vs undifferentiated HL-60 cells gene expression from GSE93996, with inflammasome related genes marked in blue. Only significant DE genes are shown (adjusted p value < 0.05).

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 8. Neutrophil accumulation in the lungs correlates with viral loads in SARS-CoV-2 infected
 mice. Female BALB/c mice were intranasally inoculated with 5\*10<sup>5</sup> TCID50 SARS-CoV-2 MaVie strain
 or PBS as control and euthanized at 2 dpi or 4 dpi.

(A) RNA was isolated from lungs and subjected to RT-qPCR targeting viral subE and GAPDH as housekeeping gene. The relative expression of subE was measured using the comparative Ct method as compared to mock-infected control (in which subE was undetectable but set to 40 Ct) \*\*\*\* p < 0.0001. P values calculated with Welch's t-test.</li>

(B) Quantification based on morphometric analysis that determines the area of immunolabelling for
 SARS-CoV-2 nucleoprotein in relation to total tissue area. \*\*\*p<0.001. P values calculated with Welch's</li>
 t-test.
 Quantification of Ly-6G based on morphometric analysis that determines the area of immunolabelling

(C) Quantification of Ly-6G based on morphometric analysis that determines the area of immunolabelling for Ly6G in relation to total tissue area in mock-infected controls. \*\*\*\* p < 0.0001. P values calculated with ordinary one-way ANOVA using Tukey's multiple comparisons test. Black line represents the mean.

(**D**) Left column: immunohistochemistry for SARS-CoV-2 nucleoprotein; right column: immunohistochemistry for Ly6G (neutrophil marker), hematoxylin counterstain. Bars =  $500 \mu m$  (large images) and  $50 \mu m$  (insets).

993At 2 dpi (top), the arrow points at a bronchus with viral antigen expression in epithelial cells. A close-up994of the bronchus (bottom; B: bronchial lumen) shows degenerated and slough off antigen positive epithelial995cells. Adjacent alveoli exhibit viral antigen expression in typeI (arrowhead) and typeII (arrow)996pneumocytes. The overview (top) shows neutrophils between the infected bronchial (arrow) epithelial997cells, in parenchymal areas (arrowhead; right inset) and in capillaries (arrowheads). A close-up of the998bronchus (bottom; B: bronchial lumen) highlights numerous neutrophils between degenerate (arrowheads)999epithelial cells.

1000At 4 dpi (middle), there are focal areas with antigen expression in alveolar epithelial cells and infiltrating<br/>macrophages. Neutrophils are present among the infiltrating cells (arrow) as individual cells (inset:<br/>arrows) or in aggregates (inset: arrowhead).1003The bottom shows the lung of a mock-infected control animal. There is no viral antigen expression.

1003The bottom shows the lung of a mock-infected control animal. There is no viral antigen expression.1004Staining for Ly6G depicts individual neutrophils in larger vessels (inset: arrow) or in capillaries (inset:1005arrowheads).

1006 1007 1008

988

989

990

991

992

| 1009 | Figure 9. Neutrophils of SARS-CoV-2 infected mice display increased caspase1 activation ability            |
|------|--|
| 1010 | that is dependent on IFN-I.  |
| 1011 | Female BALB/c mice were intranasally inoculated with 5* 10 <sup>5</sup> TCID50 SARS-CoV-2 MaVie strain or  |
| 1012 | PBS as control. Lungs were harvested at 2 and 4 dpi and Ly-6G+ neutrophils isolated based on positive      |
| 1013 | selection with magnetic beads. RNA was isolated and subjected to transcriptomic analysis by RNA-seq.       |
| 1014 | (A) Principal component analysis (PCA) of the PBS-inoculated control and SARS-CoV-2 infected mice          |
| 1015 | lung neutrophil RNA-seq samples. (B) Heatmap of the top DEGs. (C) Volcano plots of DEGs between            |
| 1016 | neutrophils isolated from SARS-CoV-2 infected mice versus uninfected PBS-inoculated mice. Blue points      |
| 1017 | represent significant terms (adjusted p-value < 0.05), while smaller gray points represent non-significant |
| 1018 | terms. Relevant inflammasome and interferon related genes are shown with larger and darker blue points.    |
| 1019 | (D) Caspase1 activity in isolated mice neutrophils following a 2-h stimulation with nigericin was          |
| 1020 | assessed by a bioluminescence method (Caspase-Glo® 1 Inflammasome Assay).                                  |
| 1021 | (E-G Mice were intraperitoneally inoculated with 250 µg anti-IFNAR or IgG1 isotype control directly        |
| 1022 | after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally PBS-   |
| 1023 | inoculated control mice without intraperitoneal injection).  |
| 1024 | (E) Caspase1 activity was assessed following a 2-h stimulation with nigericin by bioluminescence           |
| 1025 | method.  |
| 1026 | (F-G) RNA was isolated from isolated neutrophils and fold change mRNA expressions of (C) Caspase1          |
| 1027 | (Casp1) and (D) IL-1β (IL1b) in isotype control and anti-IFNAR treated infected mice as compared to        |
| 1028 | mock-infected control mice assessed by RT-qPCR.  |
| 1020 | DEC differentially engrand areas   |

- DEG = differentially expressed genes.
- 1029 1030 1031 1032 p < 0.05, and p < 0.01. P values for D, E and H panels were calculated with ordinary one-way ANOVA using Tukey's multiple comparisons. Welch's t-test was used for panels F and G. Data presented as mean  $\pm$  SD.

| 1033<br>1034 | Supplementary figure legends   |
|--------------|--|
| 1035         | Supplementary Figure 1. Enriched pathways and differentially expressed genes in severe COVID-              |
| 1036         | 19 PMNs and LDGs.  |
| 1037         | (A-B) Volcano plots of enriched gene sets in severe COVID-19 PMNs versus (A) HC PMNs and (B)               |
| 1038         | severe COVID-19 LDGs, using KEGG database. Each point represents a single gene set, where the x-axis       |
| 1039         | measures its odds ratio, while the y-axis shows its -log(p-value). Blue points represent significant terms |
| 1040         | (adjusted p-value < 0.05), where darker points represent more significant terms, while smaller gray points |
| 1041         | represent non-significant terms.   |
| 1042         | (C-D) Volcano plots of DEGs between severe COVID-19 PMNs versus (C) HC PMNs and (D) severe                 |
| 1043         | COVID-19 LDGs. Blue points represent significant terms (adjusted p-value < 0.05), while smaller gray       |
| 1044         | points represent non-significant terms. Relevant inflammasome related or -predicted genes based on the     |
| 1045         | literature, according to GENESHOT (34), are shown with a larger and darker blue point.                     |
| 1046         | (E-F) Pie charts of interferon and inflammasome related genes, according to GENESHOT from the              |
| 1047         | identified DEGs in severe COVID-19 PMNs, compared to (E) HC PMNs and (F) severe COVID-19                   |
| 1048         | LDGs.  |
| 1049         | (G-H) Volcano plots of (G) severe COVID-19 PMNs versus mild COVID-19 PMNs and (H) mild                     |
| 1050         | COVID-19 PMNs vs HC PMN. Blue points represent significant terms (adjusted p-value < 0.05), while          |
| 1051         | smaller gray points represent non-significant terms. Relevant inflammasome related or predicted genes      |
| 1052         | based on the literature, according to GENESHOT, are shown with a larger and darker blue point.             |
| 1053         | DEG = differentially expressed genes.  |

| 1054 | Supplementary Figure 2. Differential expression of interferon and inflammasome related genes in           |
|------|---|
| 1055 | <b>PMNs during COVID-19.</b> RNA was extracted from isolated HC PMNs (n = 8-13) versus severe COVID-      |
| 1056 | 19 PMNs ( $n = 29-32$ ) and subjected to comparative RT-qPCR using specific primers for OAS1, OAS2,       |
| 1057 | IFIT1, IFI16, caspase1, caspase5, IL1B, NLRC4, NLRC5, NLRP3 and NAIP. *p < 0.05, **p < 0.01, ***p         |
| 1058 | $< 0.001$ and **** p < 0.0001. P values calculated with Mann-Whitney U-test. Data presented as mean $\pm$ |
| 1059 | SD.   |
| 1060 |   |
| 1061 |   |

| 1062 | Supplementary Figure 3. Ex vivo stimulation of isolated PMNs.  |
|------|--|
| 1063 | (A-C) Effect of different inflammasome specific inhibitors in cytokine secretion. (A) Effect of  |
| 1064 | inflammasome inhibitor MCC950 (2 µg/ml) and YVAD (20 µg/ml) on LPS or IFN-I primed (4-h) and   |
| 1065 | nigericin activated (4-h) IL-1 $\beta$ secretion in the supernatant of healthy control PMNs (n = 8). ( <b>B-C</b> ) Effect                             |
| 1066 | of inflammasome inhibitor MCC950 (2 µg/ml, added simultaneously with nigericin) on LPS or IFN-I  |
| 1067 | primed (4-h) and nigericin activated (20-h) (B) IL-1β and (C) IL-18 secretion in the supernatant of healthy  |
| 1068 | control PMN ( $n = 3$ ).   |
| 1069 | (D) Gene expressions in HC and COVID-19 PMNs after LPS or IFN-I stimulation. A comparison of gene  |
| 1070 | expression in isolated healthy control PMNs versus COVID-19 PMNs after ex vivo stimulation with LPS  |
| 1071 | or IFN-I. Extracted RNA was subjected to comparative RT-qPCR using specific primers for NLRP3,   |
| 1072 | NLRC4, NAIP and CASP5 (n = 4-8 for HC PMN and 6-9 for COVID-19 PMN). *p < 0.05. Two-way  |
| 1073 | ANOVA with Tukey's multiple comparison test was applied. Data were presented as mean $\pm$ SD.   |
| 1074 | * $p < 0.05$ , ** $p < 0.01$ , *** $p < 0.001$ , **** $p < 0.0001$ . P values calculated with Kruskal-Wallis test. Data                                |
| 1075 | presented as mean ± SD. <i>IFN</i> = <i>interferon type I</i> , <i>LPS</i> = <i>lipopolysaccharide</i> , <i>Nig</i> = <i>nigericin</i> , <i>YVAD</i> = |
| 1076 | tetrapeptide caspase1 inhibitor Tyr-Val-Ala-Asp.   |
| 1077 |  |

1078 Supplementary Figure 4. Expression of inflammasome related genes in mature and immature 1079 neutrophils from COVID-19 PBMCs. The fraction of mature and immature neutrophils cells expressing 1080 17 inflammasome related genes identified in Figure 7B (shown in black and blue, respectively) are shown 1081 in a bar graph. For each gene, the proportion of expressing cells is shown in light blue, while the proportion 1082 of negative or not-expressing cells is shown in gray. Zoomed-in bar graph depicts the proportion of mature 1083 and immature cells expressing each gene.

1084

| 1085<br>1086<br>1087         | <b>Supplementary Figure 5. Dynamics of animal weight and impact of α-IFNAR treatment in SARS-CoV-2 infected mice.</b> Female BALB/c mice were intranasally inoculated with 5* 10 <sup>5</sup> TCID50 SARS-CoV-2 MaVie strain or PBS as control  |
|------------------------------|---|
| 1087<br>1088<br>1089<br>1090 | (A) Daily tracking of animal weight performed throughout the experiment ( $n = 8$ for SARS-CoV-2 infected animals, $n = 2$ for PBS-inoculated animals). The weights of the mice euthanized at 2 dpi ( $n = 26$ ) did not show significant differences and are not reported.           |
| 1091<br>1092<br>1093         | ( <b>B-C</b> ) Mice were intraperitoneally inoculated with 250 $\mu$ g anti-IFNAR or IgG1 isotype control directly after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally PBS-inoculated control mice without intraperitoneal injection) |
| 1094                         | (B) RNA was isolated from mouse lungs and subjected to RT-qPCR targeting the replication-intermediate   |
| 1095<br>1096                 | subgenomic E gene and GAPDH as housekeeping gene. RNA levels were assessed based on cycle threshold Ct levels. The expression levels of the target gene SubE were measured and normalized to  |
| 1097                         | GAPDH levels using the comparative Ct method ( $\Delta\Delta$ Ct). The fold change values were calculated by the  |
| 1098<br>1099                 | formula $2^{-(-\Delta\Delta Ct)}$ , representing the relative gene expression compared to the PBS mock-infected control (in which subE was undetectable but set to 40 Ct). No significant differences are seen between the two  |
| 1100                         | groups.   |
| 1101                         | (C) Histological features, viral antigen expression and extent of neutrophil influx and damage in the lung of SARS CoV 2 infacted $PALP/C$ mice often isotrop control and arti UNAP treatment at 2dni   |
| 1102                         | Left column: Control isotype treated mice: right column: anti IENAR treated mice. HE stain (top layer)  |
| 1103                         | and immunohistology hematoxylin counterstain (all other images) Bars: 250 µm (operview images) and  |
| 1105                         | 25 µm (insets).   |
| 1106                         | In control isotype treated mice, the lung exhibits degeneration and loss of bronchial and bronchiolar   |
| 1107                         | epithelial cells (HE stain: arrowhead; right inset), with mild inflammatory infiltration. The parenchyma  |
| 1108                         | exhibits focal areas of increased cellularity, with typeII pneumocyte activation and occasional degenerate  |
| 1109                         | alveolar epithelial cells (arrows; left inset: degenerate cells (arrowhead) and infiltrating neutrophil   |
| 1110                         | (arrow)). Staining for SARS-CoV-2 NP confirms epithelial cell infection in bronchus (arrowhead; right   |
| 1111                         | inset) and alveoli (arrow; left inset). Right inset: Viral antigen expression is seen in intact and sloughed  |
| 1112                         | off, degenerate epithelial cells. Left inset: Viral antigen expression is seen in both typeI (small arrowhead)  |
| 1113                         | and typeII (small arrow) pneumocytes; there are also degenerate positive cells (large arrowhead).   |
| 1114                         | Neutrophils (Ly6G+) are located within focal parenchymal areas of increased cellularity (arrows; left   |
| 1115                         | inset: arrowheads) and present between degenerate bronchial epithelial cells (arrowhead; right inset:   |
| 1116                         | arrowhead). Staining for histone H3 shows neutrophil degeneration/NETosis in parenchymal areas  |
| 1117                         | (arrow; left inset: arrowheads) and associated with degenerate epithelial cells (arrowhead; right inset:  |
| 1118                         | positive reaction between sloughed off epithelial cells (arrow) and between the intact epithelial layer   |
| 1119                         | (arrowhead)).   |
| 1120                         | In anti-IFNAR treated animals, the lung exhibits degeneration and loss of bronchial and bronchiolar anithalial calls (arrowhad) with mild inflammatory infiltration and individual  |
| 1121                         | epithemai cens (arrownead, right inset, arrows), with mind minaminatory initiation and mulvidual neutrophils between integet and sloughed off degenerate epithelial cells (right inset, arrowheede). The  |
| 1122                         | neurophilis between intact and sloughed off degenerate epitienial cens (fight liset, allowheads). The   |
| 1123                         | degenerate alveolar epithelial calls (arrows: left inset: degenerate calls (arrow) and infiltrating neutrophils   |
| 1124                         | (arrowhead) Staining for SARS-CoV-2 NP shows enithelial cell infection in bronchioles (arrowhead:   |
| 1125                         | right inset) and alveoli (arrow: left inset) Right inset. Viral antigen expression is seen in intact and  |
| 1120                         | sloughed off degenerate epithelial cells. Left inset: Viral antigen expression is seen in pneumocytes   |
| 1128                         | (arrow) and infiltrating macrophages (arrowheads). Neutrophils (Lv6G+) locate within focal parenchymal  |
| 1129                         | areas of increased cellularity (arrows; left inset) and are present between intact (inset: arrowhead) and   |
| 1130                         | degenerate epithelial cells (arrowhead; right inset: arrow). Staining for histone H3 shows neutrophil   |
| 1131                         | degeneration/NETosis in parenchymal areas (arrow; left inset) and associated with degenerate epithelial   |
| 1132                         | cells (arrowhead; right inset: positive reaction between sloughed off epithelial cells (arrow) and between  |
| 1133                         | the intact epithelial layer (arrowhead)).   |
| 1134                         | $Dpi = days \ post \ infection; \ NP = nucleoprotein.$  |

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295190; this version posted September 14, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### Table legends

### Table 1. Clinical parameters of hospitalized patients (n=34).

| Parameter  | Range (Mean <u>+</u> SD) or ratio |  |  |  |
|--|-----------------------------------|--|--|--|
| Age (years)  | 22 - 80 (58.41 <u>+</u> 13.63)    |  |  |  |
| Gender (male:female)                                 | 23:11                             |  |  |  |
| Hospitalization (days)                               | 3 - 38 (12 <u>+</u> 8.63)         |  |  |  |
| WHO Ordinal scale for Clinical improvement: Baseline | 1 - 6 (4 <u>+</u> 1.07)           |  |  |  |
| WHO Ordinal scale for Clinical improvement: Worst    | 2 - 8 (4 <u>+</u> 1.42)           |  |  |  |
| Deaths (count/total)                                 | 1/34                              |  |  |  |
| ICU (count/total)                                    | 9/34                              |  |  |  |
| Corticosteroid use (count/total)                     | 13/34                             |  |  |  |
| Length of stay in ICU (days)                         | 1 - 27 (7.38 <u>+</u> 9.49)       |  |  |  |
| Max CRP (mg/L)                                       | 6 - 466 (159.56 <u>+</u> 104.06)  |  |  |  |
| Min lymphocyte count (E <sup>9</sup> /L)             | 0.08 - 2.02 (0.79 <u>+</u> 0.42)  |  |  |  |
| Max neutrophil count (E <sup>9</sup> /L)             | 1.08 - 29.86 (7.85 <u>+</u> 5.73) |  |  |  |
| Sampling day neutrophil count (E <sup>9</sup> /L)    | $0.64 - 20.52 (5.65 \pm 3.95)$    |  |  |  |

The World Health Organization (WHO) Ordinal Scale for clinical improvement is a tool designed specifically to assess and measure the progression and clinical improvement of patients <sup>63</sup>. COVID-19 scoring: 1= no limitations of activity, 2= limitations of activity, 3= no oxygen therapy, 4= oxygen by mask or nasal cannulae, 5= non-invasive ventilation or high-flow oxygen, 6= invasive mechanical ventilation without other organ support, 7= invasive mechanical ventilation with other organ support, 8= dead. The baseline score represents the timepoint of the first laboratory sample taken, serving as a reference point for measuring improvement and establishing a starting point for comparison. In contrast, the worst score represents the most severe or critical state of the disease. None of the patients whose samples were used for RNA-seq underwent corticosteroid treatment. *Abbreviations: WHO*= *World Health Association. ICU* = *Intensive Care Unit. CRP* = *C reactive protein. Min* = *minimum. Max* = *maximum*.

### 1151 1152 Supplementary Table S1. qPCR primer sequences: gene-specific forward and reverse primers.

| Gene                        | Forward primer          | Reverse primer           |  |  |  |
|-----------------------------|-------------------------|--------------------------|--|--|--|
| AIM2                        | GGCCCAGCAGGAA TCTATCAG  | GAAGGGCTTCTTTGCTTTCAGTAC |  |  |  |
| NAIP                        | AAGGGATTTGTTGACATAACGGG | CAGCCGTAGTTCTTCGTAAGC    |  |  |  |
| NLRC5                       | ACAGCATCCTTAGACACTCCG   | CCTTCCCCAAAAGCACGGT      |  |  |  |
| IL1B                        | CACATGGGATAACGAGGCTT    | TCCAGCTGTAGAGTGGGGCTT    |  |  |  |
| CASP1                       | GCTTTCTGCTCTTCCACACC    | TCCTCCACATCACAGGAACA     |  |  |  |
| CASP4 CAAGAGAAGCAACGTATGGCA |                         | AGGCAGATGGTCAAACTCTGTA   |  |  |  |
| CASP5                       | TTCAACACCACATAACGTGTCC  | GTCAAGGTTGCTCGTTCTATGG   |  |  |  |
| IFI16                       | TCCTCAGATGCCTCCATCAAC   | CAGGTTCAGTCTTCAGTCTTGGT  |  |  |  |
| IFIT5                       | TAAAAAGGCCTTGGAGGTG     | CCAGGTCTGTGTAGGCAAAT     |  |  |  |
| IRF7                        | GCTGGACGTGACCATCATGTA   | GGGCCGTATAGGAACGTGC      |  |  |  |
| IFIT1                       | GCGCTGGGTATGCGATCTC     | CAGCCTGCCTTAGGGGAAG      |  |  |  |
| IFI6                        | GGTCTGCGATCCTGAATGGG    | TCACTATCGAGATACTTGTGGGT  |  |  |  |
| OAS1                        | TGTCCAAGGTGGTAAAGGGTG   | CCGGCGATTTAACTGATCCTG    |  |  |  |
| OAS2                        | CTCAGAAGCTGGGTTGGTTTAT  | ACCATCTCGTCGATCAGTGTC    |  |  |  |
| GAPDH                       | TTGGCTACAGCAACAGGGTG    | GGGGAGATTCAGTGTGGTGG     |  |  |  |

1153 1154

## 1155 1156

### Supplementary Table S2. Histological changes as well as SARS-CoV-2 nucleoprotein and RNA expression in female BALB/C mice infected with SARS-CoV-2. A. Experiment 1. Infected animals were euthanized and examined at 2 and 4 days post infection.

Histological changes, viral antigen and Ly6G expression<sup>1</sup> in lungs Viral subE (and Infection, dpi GAPDH) RNA [Animal no] Cts<sup>2</sup> 5 x 10^5 PFU, 2 dpi HE: bronchioles with abundant degen EC (in place and sloughed off); 15.12 (13.47) parenchymal areas with type II pn activation, occ degen AEC and increased [1.1.1] cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Lv6G: increase in NL in lumen of vessels and capillaries; NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC 5 x 10^5 PFU, 2 dpi HE: bronchioles with abundant degen EC (in place and sloughed off); 15.92 (13.79) [1.1.2] parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen): most alveoli with pos AEC Lv6G: increase in NL in lumen of vessels and capillaries. NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC 5 x 10^5 PFU, 2 dpi HE: bronchioles with abundant degen EC (in place and sloughed off); 15.56 (13.83) [1.1.3]parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen): most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC 5 x 10^5 PFU, 2 dpi 16.33 (14.81) HE: bronchioles with abundant degen EC (in place and sloughed off); [1.1.4]parenchymal areas with type II pn activation, occ degen AEC and increased cellularity vAg: extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC Ly6G: increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) 5 x 10^5 PFU, 4 dpi HE: one bronchiole with degen EC (in place and sloughed off), others 31.68 (11.64) unaltered; large parenchymal area with extensive type II pn activation, degen [1.2.1] AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with extensive expression (almost all BEC, some also degen), others with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected areas) Ly6G: some increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli in affected area (partly degen) 5 x 10^5 PFU, 4 dpi HE: bronchioles with a few degen EC (in place or sloughed off), others 31.86 (11.78) [1.2.2] unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) 5 x 10^5 PFU, 4 dpi HE: bronchioles with a few degen EC (in place or sloughed off), others 31.33 (11.71) [1.2.3] unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) vAg: some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) 5 x 10^5 PFU, 4 dpi HE: bronchioles with rare degen EC, most unaltered; parenchymal area with 35.02 (11.89) type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) [1.2.4] vAg: some bronchioles with a few to several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) Ly6G: some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen) PBS (control), 2 dpi Lung: NHA n.d., set to 40 [1.3.1] vAg: neg (13.65)Ly6G: a few individual NL in lumen of vessels and capillaries Lung: NHA PBS (control), 2 dpi n.d., set to 40 [1.3.2] vAg: neg (15.66)Ly6G: a few individual NL in lumen of vessels and capillaries

| PBS (control), 2 dpi | Lung: NHA   | n.d., set to 40 |
|----------------------|---|-----------------|
| [1.3.3]              | vAg: neg  | (14.32)         |
|                      | Ly6G: a few individual NL in lumen of vessels and capillaries |                 |
| PBS (control), 2 dpi | Lung: NHA   | n.d., set to 40 |
| [1.3.4]              | vAg: neg  | (14.57)         |
|                      | Ly6G: a few individual NL in lumen of vessels and capillaries |                 |

B. Experiment 3. Infected animals were treated with control isotype or IFNAR blocking antibody prior to euthanization and examination at 2 days post infection.

| Infection, treatment  | Histological changes, viral antigen (vAg), Ly6G and histone H3 expression <sup>1</sup>   | Viral subE (and  |
|-----------------------|--|------------------|
| [Animal no, sex, age] | in lungs   | GAPDH) RNA       |
|                       |  | Cts <sup>2</sup> |
| 5 x 10^5 PFU, control | <b>HE:</b> bronchus and connected bronchiole with abundant degen EC (in place or   | 14.75 (12.63)    |
| isotype               | sloughed off); endothelial cell activation in adjacent muscular veins, with some   |                  |
| [3.1.1]               | leukocyte adhesion; adjacent parenchymal areas with type II pn activation, occ   |                  |
|                       | degen AEC and increased cellularity $y = \frac{1}{2} \frac{1}$ |                  |
|                       | (degen) and large adjacent areas of alweeli with pos AEC   |                  |
|                       | <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries in affected areas. NL  |                  |
|                       | in lumen of bronchioles and alveoli (partly degen)   |                  |
|                       | H3: pos reaction in areas with degen NL (lumen of bronchioles, affected  |                  |
|                       | alveoli)   |                  |
| 5 x 10^5 PFU, control | HE: some bronchioles with abundant degen EC (in place or sloughed off);  | 16.61 (11.54)    |
| isotype               | endothelial cell activation in some adjacent vessels; (adjacent) parenchymal   |                  |
| [3.1.2]               | areas with type II pn activation, occ degen AEC and increased cellularity  |                  |
|                       | vAg: extensive expression in some bronchioles (almost all BEC, also degen),  |                  |
|                       | large (adjacent) areas of alveoli with pos AEC   |                  |
|                       | LyoG: mild increase in NL in lumen of vessels and capillaries in affected areas,   |                  |
|                       | H3: nos reaction in areas with degen NL (lumen of bronchioles affected   |                  |
|                       | alveoli)   |                  |
| 5 x 10^5 PFU, control | <b>HE:</b> bronchioles with abundant degen EC (in place or sloughed off); endothelial  | 16.00 (12.71)    |
| isotype               | cell activation in some muscular veins, with leukocyte rolling and   |                  |
| [3.1.3]               | subendothelial infiltration (vasculitis), other vessels packed with leukocytes;  |                  |
|                       | (adjacent) parenchymal areas with type II pn activation, occ degen AEC and   |                  |
|                       | increased cellularity  |                  |
|                       | vAg: extensive expression in bronchioles (patches of BEC to almost all BEC,  |                  |
|                       | also degen), large (adjacent) areas of alveoli with pos AEC  |                  |
|                       | Lyog: find increase in NL in fumer of vessels and capitalies in affected areas,  |                  |
|                       | H3: extensive nos reaction in areas with degen NL (lumen of bronchioles  |                  |
|                       | affected alveoli)  |                  |
| 5 x 10^5 PFU, control | HE: bronchus and bronchioles with abundant degen EC (in place or sloughed  | 15.07 (13.83)    |
| isotype               | off); endothelial cell activation in some muscular veins, with leukocyte rolling   |                  |
| [3.1.4]               | and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ  |                  |
|                       | degen AEC and increased cellularity  |                  |
|                       | vAg: extensive expression in bronchioles (patches to almost all BEC, also  |                  |
|                       | degenerate), large (adjacent) areas of alveoli with pos AEC  |                  |
|                       | LyoG: mild increase in NL in lumen of vessels and capillaries in affected areas,<br>NL in lumen of bronchicles and alweeli (partly degenerate)   |                  |
|                       | H3: nos reaction in areas with degen NL (lumen of bronchioles affected   |                  |
|                       | alveoli): most extensive in alveoli  |                  |
|                       |  |                  |
| 5 x 10^5 PFU,         | HE: bronchus and connected bronchiole with abundant degen EC (in place or  | 13.98 (12.44)    |
| anti-IFNAR            | sloughed off); endothelial cell activation in muscular veins, with some leukocyte  |                  |
| [3.2.1]               | adhesion; patchy parenchymal areas with type II pn activation, occ degen AEC   |                  |
|                       | and increased cellularity  |                  |
|                       | vAg: extensive expression in bronchioles (abundant to almost all BEC, also   |                  |
|                       | degen), and large areas of alveon with pos AEC   |                  |
|                       | in lumen of bronchioles and alveoli (nartly degen)   |                  |
|                       | <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected   |                  |
|                       | alveoli)   |                  |
| 5 x 10^5 PFU,         | HE: bronchioles with occ degen EC (in place or sloughed off); endothelial cell   | 14.90 (13.12)    |
| anti-IFNAR            | activation in muscular veins, with some leukocyte adhesion; parenchymal areas  |                  |
| [3.2.2]               | with type II pn activation, occ degen AEC and increased cellularity  |                  |
|                       | vAg: extensive expression in bronchus/bronchioles (almost all BEC, also  |                  |
|                       | degen), and large areas of alveoli with pos AEC  |                  |
|                       | <b>Lyou:</b> increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of branchicles and alwach (norther dense)   |                  |
|                       | In further of bronchioles and alveon (partly degen)  |                  |
|                       | alveoli)   |                  |

| 5 x 10^5 PFU,<br>anti-IFNAR<br>[3.2.3] | <ul> <li>HE: infected bronchus with a few degen EC (in place); mild endothelial cell activation in some adjacent vessels; (adjacent) parenchymal areas with type II pn activation and increased cellularity</li> <li>vAg: a few individual EC in bronchus and some bronchioles, one with all EC pos, adjacent large patches of alveoli with pos AEC</li> <li>Ly6G: increase in individual NL in lumen of vessels and capillaries (mainly in affected areas), a few NL in lumen and between EC of infected bronchiole, and in alveoli in affected areas</li> <li>H3: rare pos reaction in alveoli</li> </ul>   | 28.79 (14.09)              |
|--|---|----------------------------|
| 5 x 10^5 PFU,<br>anti-IFNAR<br>[3.2.4] | <ul> <li>HE: infected bronchioles with variable amount of degen EC (in place or sloughed off); endothelial cell activation in some vessels, with leukocyte rolling and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity</li> <li>vAg: bronchus and bronchioles with individual, patches of to almost all BEC pos (also degen) and cell free viral Ag in lumen, large (adjacent) areas of alveoli with pos AEC (also degen)</li> <li>Ly6G: increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen)</li> <li>H3: extensive pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)</li> </ul> | 13.54 (13.33)              |
|  |   |                            |
| PBS (control), none [3.3.1]            | Lung: NHA<br>vAg: neg<br>Ly6G: a few individual NL in lumen of vessels and capillaries  | n.d., set to 40<br>(10.20) |
| PBS (control), none<br>[3.3.2]         | Lung: NHA<br>vAg: neg<br>Ly6G: a few individual NL in lumen of vessels and capillaries  | n.d., set to 40<br>(11.04) |
| PBS (control), none<br>[3.3.3]         | Lung: NHA<br>vAg: neg<br>Ly6G: a few individual NL in lumen of vessels and capillaries  | n.d., set to 40<br>(14.06) |
| PBS (control), none<br>[3.3.4]         | Lung: NHA<br>vAg: neg<br>Ly6G: a few individual NL in lumen of vessels and capillaries  | n.d., set to 40 (13.70)    |

1166

1167

The age of the infected animals were 9 weeks in experiment 1 and 8 weeks in experiment 3; alv – alveolar; BEC - bronchiolar epithelial cells; degen - degenerate (this also includes apoptotic and/or necrotic); EC - epithelial cells; F - female; HE - histological features assessed in a hematoxylin-eosin stained section; incl – including; M – male; neg – negative; NHA – no histological abnormality; NL – neutrophilic leukocytes (i.e. neutrophils); occ – occasional; pc – pneumocytes; pos – positive; pv – perivascular; vAg - viral antigen; we - weeks; n.d. - not detected

1168 <sup>1</sup> Viral antigen and Ly6G expression determined by immunohistochemistry.

1169 <sup>2</sup> Obtained RT-qPCR cycle threshold values (Cts) for viral subgenomic E gene (subE) as a measure of 1170 viral replication and GADPH mRNA as the housekeeping gene. As expected, for PBS control animals no 1171 Ct value for viral subE was obtained. The subE Ct for control animals was set to the detection limit of 40 1172 to facilitate fold change calculations presented in Figure 8A and Supplementary Fig. 5B.



preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

It is made available under a CC-BY-NC-ND 4.0 International license .



В

Α



В

## ORA KEGG



## ORA KEGG

Α

С

Ε





F











G

















|                   | Age   | Hospital LOS | WHO Ordinal scale | Lymphocytes (min) | Neutrophil count | IL-1β (LPS+nig) | IL-1β (IFN+nig) | Casp1 (nigericin) | Calprotectin |
|-------------------|-------|--------------|-------------------|-------------------|------------------|-----------------|-----------------|-------------------|--------------|
| Age               | 1.00  | -0.22        | -0.23             | 0.44              | -0.15            | -0.10           | -0.02           | -0.42             | -0.26        |
| Hospital LOS      | -0.22 | 1.00         | 0.23              | -0.38             | 0.08             | 0.04            | -0.15           | 0.29              | 0.26         |
| WHO Ordinal scale | -0.23 | 0.23         | 1.00              | -0.41             | 0.47             | -0.51           | -0.58           | 0.25              | 0.19         |
| Lymphocytes (min) | 0.44  | -0.38        | -0.41             | 1.00              | -0.27            | -0.05           | 0.20            | -0.41             | -0.34        |
| Neutrophil count  | -0.15 | 0.08         | 0.47              | -0.27             | 1.00             | -0.47           | -0.82           | -0.04             | -0.08        |
| IL-1β (LPS+nig)   | -0.10 | 0.04         | -0.51             | -0.05             | -0.47            | 1.00            | 0.70            | 0.14              | 0.26         |
| IL-1β (IFN+nig)   | -0.02 | -0.15        | -0.58             | 0.20              | -0.82            | 0.70            | 1.00            | 0.12              | 0.20         |
| Casp1 (nigericin) | -0.42 | 0.29         | 0.25              | -0.41             | -0.04            | 0.14            | 0.12            | 1.00              | 0.81         |
| Calprotectin      | -0.26 | 0.26         | 0.19              | -0.34             | -0.08            | 0.26            | 0.20            | 0.81              | 1.00         |
|                   |       |              |                   |                   |                  |                 | •               |                   |              |
| 4                 | _     |              | 0.5               |                   | -                |                 | 0.5             |                   | 4            |
| -1.0              |       |              | -0.5              |                   | U                |                 | 0.5             |                   | 1            |

Α

В



С











Η





IFN LPS MOCH CCOSO WAD MOCH CCOSO

F

400 - HL-60

(ILI-1b (pg/ml) 00 01

MOCK





Ε





D

SARS-CoV-2 NP

Ly6G





Control SARS-CoV-2 infected Nigericin



IL1b mRNA

G



Cxcl10 Cxcl10 Infil2 Cxcl20 Infil2 Cxcl20 Infil2 Gbp3 Gbp1 Inf206 Gbp2 Gbp3 Gbp2 Gbp3 Gbp4 Infil1 Infil2 Gbp3 Gbp4 Bc2 Infil2 Infil2 Gbp4 Gbp4 Bc2 Infil2 Infil2 Gbp5 Gcd2 Ccd2 Infil2 Infil2 Infil2 Cd2 Infil2 Infil2

Casp1 mRNA

F





